POPULARITY
4 episodes with ctx
3 episodes with ctx
4 episodes with ctx
2 episodes with ctx
In the wake of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® put together an X Spaces discussion hosted by Stephen Liu, MD, and Joshua Sabari, MD, to highlight the most intriguing and practice-changing lung cancer abstracts. Discussed topics ranged from long-term follow-up with commonplace therapies to an analysis of what time of day is the best to administer immunochemotherapy. Liu, an associate professor of Medicine at Georgetown University, and the director of Thoracic Oncology and head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, and Sabari, an assistant professor in the Department of Medicine at the NYU Grossman School of Medicine, and the director of High Reliability Organization Initiatives at the Perlmutter Cancer Center, shared expert insights on the latest non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) breakthroughs. Trials of note that they discussed included: The phase 3 DeLLphi-304 trial (NCT05740566) - Tarlatamab (Imdelltra) versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): primary analysis of Ph3 DeLLphi-304.1 The phase 3 IMforte trial (NCT05091567) - Lurbinectedin (Zepzelca; lurbi) + atezolizumab (Tecentriq; atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): primary results of the phase 3 IMforte trial.2 The phase 3 CheckMate 816 trial (NCT02998528) - Overall survival with neoadjuvant nivolumab (Opdivo; NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.3 The phase 3 PACIFIC15 trial (NCT05549037) - Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non–small cell lung cancer.4 The phase 3 Beamion LUNG-1 trial (NCT04886804) - Patient-reported outcomes (PRO) evaluating physical functioning and symptoms in patients with pretreated HER2-mutant advanced non–small cell lung cancer (NSCLC): results from the Beamion LUNG-1 trial.5 The phase 3 ARTEMIA trial (NCT06472245) - Phase 3 trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non–small cell lung cancer and secondary resistance to immunotherapy. References Rudin C, Mountzios G, Sun L, et al. Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): primary analysis of Ph3 DeLLphi-304. J Clin Oncol. 2025;43(suppl 17):LBA8008. doi:10.1200/JCO.2025.43.17_suppl.LBA8008 Paz-Ares L, Borghaei H, Liu SV, et al. Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): primary results of the phase 3 IMforte trial. J Clin Oncol. 2025;43(suppl 16):8006. doi:10.1200/JCO.2025.43.16_suppl.8006 Forde PM, Spicer JD, Provencio M, et al. Overall survival with neoadjuvant nivolumab + chemotherapy in patients with resectable NSCLC in CheckMate 816. J Clin Oncol. 2025;43(suppl 17):LBA8000. doi:10.1200/JCO.2025.43.17_suppl.LBA8000 Zhang Y, Huang Z, Zeng L, et al. Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non-small cell lung cancer. J Clin Oncol. 2025;43(suppl 16):8516. doi:10.1200/JCO.2025.43.16_suppl.8516 Sabari JK, Nadal E, Hendriks L, et al. Patient-reported outcomes (PRO) evaluating physical functioning and symptoms in patients with pretreated HER2-mutant advanced non-small cell lung cancer (NSCLC): results from the Beamion LUNG-1 trial. J Clin Oncol. 2025;43(suppl 16):8620. doi:10.1200/JCO.2025.43.16_suppl.8620 Liu SV, Guibert C, Tostivint EP, et al. Phase 3 trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy. J Clin Oncol. 2025;43(suppl 16):TPS8651. doi:10.1200/JCO.2025.43.16_suppl.TPS8651
CTX is a rare metabolic disease that can cause seizures, developmental delays, and intellectual disability. Now, a diagnostic test that can detect the condition early is available, and a treatment that can prevent the disease's serious effects has won regulatory approval. We spoke to Bart Duell, professor of medicine at Oregon Health Sciences University, about CTX, the role OHSU played in developing a diagnostic and advancing a treatment for CTX; and the critical interplay between academic medical centers, patient advocates, and drug developers to address the needs of people with rare diseases.
Maximizing Fitness, Fat Loss & Running Through Perimenopause
In this empowering episode, your host Louise, a multi award-winning women's integrative health practitioner, performance scientist and one of the world's leading exercise physiologists specializing in the needs of active women and recreational runners, opens up about her personal journey through the broken U.S. healthcare system—sharing real frustrations, devastating setbacks, lessons learned, and practical strategies to help you advocate for your own vibrant health and fitness. From being dismissed for "looking healthy" to getting denied essential labs, she highlights the challenges many women face, especially ambitious active women facing hormone challenges and frustrating peri/menopause symptoms.You'll learn how to prepare for a doctor's visit, including ideas of what labs and screenings to request, how to present your health history effectively, and why walking in with confidence and clarity matters. She breaks down how to blend traditional and integrative medicine for optimal care and stresses the importance of tuning into your body over relying solely on expensive tests.Whether you're trying to get answers, ditch symptoms, reverse setbacks or take a more proactive approach to your holistic wellness, this episode will leave you informed, fired up, and equipped to take charge of your healthcare journey!Ready to level up your knowledge of getting the holistic care you deserve? Let's freaking go! Tune in and take action today!Check out Function Health, using our referral link here: https://my.functionhealth.com/signup?code=LVALENTINE11&_saasquatch=LVALENTINE11 If you use our link, a small portion of the sale goes back to support our work at Breaking Through Wellness & this podcast. Thank you!Get our free nutrition guide, weekly newsletter & explore our industry-leading Badass Breakthrough Academy here: https://www.breakingthroughwellness.com/Get our podcast listener discount of 20% off Kion's science-backed essential amino acids & more at https://www.getkion.com/maximizing Code “LOUISE” saves on all of your future orders.Episode Highlights:(0:00) Intro(2:10) Why women's healthcare is failing and the personal motivation behind this episode(4:30) Early struggles with hormonal health and long-term impact(5:56) What Breaking Through Wellness offers and how it supports clients(7:04) How to advocate confidently at your doctor's visit(9:10) The problem with denied labs like Vitamin D and A1C(10:54) Using Function Health and customizing lab insights(12:45) Why blood tests aren't always best for hormone tracking(14:25) The frustration of functional medicine being dismissed(19:49) Advocating with lab printouts and history(22:19) Preventive screenings to include in your checklist(25:11) Liver health and when to request an ultrasound(29:54) Advocating for cardiology referrals at age 40(32:38) DEXA scans, bone health, and why you should start early(35:07) Advanced bone health labs (CTX and P1NP)(38:18) What to do if you're denied or dismissed(41:01) A look at intTune in weekly to "Maximizing Fitness, Physique, and Running Through Perimenopause" for a simple female-specific science-based revolution. Let's unlock our best with less stress!I'd love to connect!Instagram
In this video, Dr. Doug Lucas discusses the importance of bone health tests, specifically the P1NP and CTX markers, in reversing osteoporosis. He highlights the limitations of traditional medical practices, the challenges faced by patients in obtaining these tests, and the need for a new approach that includes natural therapies and community support. The conversation emphasizes the significance of understanding bone turnover markers and the importance of investing in one's health for better outcomes.
Have you just been diagnosed with osteoporosis? Before you panic, listen to this episode to take control of your bone health journey. Today, I'm in the hot seat as I'm interviewed by my husband, Dr. Craig Bissinger, an experienced OB-GYN. Usually, I ask the questions, but the tables have turned this time! Together, we dive deep into what to do after receiving an osteoporosis or osteopenia diagnosis. From essential tests to understanding your bone health, I share expert advice on advocating for yourself during medical visits. Discover the importance of bone density scans, the role of root causes like inflammation and gut health, and what questions to ask your doctor to ensure a comprehensive treatment plan. Tune in to empower yourself with the knowledge to improve your bone health and overall wellness and become an active participant in your care. “When we address the root causes and address it that way, then really miracles happen. Besides bones getting better, everything gets better.” ~ Margie Bissinger In this episode: [00:11] - Key info to know after an osteoporosis diagnosis [01:30] - Why patients are often unprepared for their doctor visits [03:01] - Beyond bone density: determining the root cause of bone loss [05:35] - Understanding bone builders (osteoblasts) and destroyers (osteoclasts) [06:52] - Must-have blood tests: CTX and P1NP [09:41] - Inflammation's role in bone loss [10:40] - Combining medication with natural approaches [15:19] - Blood sugar levels and other risk factors [17:04] - Calcium levels and parathyroid health [25:12] - Lifestyle changes that boost bone health [28:42] - Where to get good quality supplements [31:25] - How often should you get follow-up tests? Resources mentioned - Osteoporosis Testing Sheet - https://www.happyboneshappylife.com/osteoporosis-tests - Discounted supplements through Fullscript - https://us.fullscript.com/welcome/mbissinger More about Margie - Website - https://margiebissinger.com/ - Facebook - https://www.facebook.com/p/Margie-Bissinger-MS-PT-CHC-100063542905332/ - Instagram - https://www.instagram.com/margiebissinger/?hl=en DISCLAIMER – The information presented on this podcast should not be construed as medical advice. It is not intended to replace consultation with your physician or healthcare provider. The ideas shared on this podcast are the expressed opinions of the guests and do not always reflect those of Margie Bissinger and Happy Bones, Happy Life Podcast. *In compliance with the FTC guidelines, please assume the following about links on this site: Some of the links going to products are affiliate links of which I receive a small commission from sales of certain items, but the price is the same for you (sometimes, I even get to share a unique discount with you). If I post an affiliate link to a product, it is something that I personally use, support, and would recommend. I personally vet each and every product. My first priority is providing valuable information and resources to help you create positive changes in your health and bring more happiness into your life. I will only ever link to products or resources (affiliate or otherwise) that fit within this purpose.
On this week's episode I have on guest Tony Carlino to talk about his recent feat of benching 1200lbs, something only 1 other person in history has done! We also discuss more about equipped bench press and the upcoming events he is competing. We also talk a bit about his background and what it's like training at CTX in Florida. --- Support this podcast: https://podcasters.spotify.com/pod/show/liftsmith/support
Welcome back to another enlightening episode of The Hormone Prescription Podcast! This week, we dive deep into a topic that resonates with so many of us: bone health. We often think we're doing enough by following generic health programs, but what if those programs fall short when it comes to bone health? What if there's a better way to ensure stronger, healthier bones?
I've been getting so many questions about Osteoporosis and bone health. So, I'm sharing another Q&A session that focuses on complementary therapies and practical actions you can take to improve your bone health. And I have another expert to help me answer the questions. Dr. Kim Millman is an integrated medical doctor and the founder of The Millman Clinic. Her passion is to help people live the rich, full lives they deserve without the burden of chronic illness. She is gifted at integrating, partnering, and customizing so that her patients get the most innovative and comprehensive medical care possible. Her training and abilities are as unique as the care that she provides. She is an expert in Functional Medicine and Nutrition Response Testing, two holistic techniques she integrates into her medical practice. Thank you for listening to another informative episode of the Happy Bones, Happy Life podcast! “What I say to everyone is that when you look at root cause factors, it is almost always multifactorial. There is not just one thing. There are many things usually. And all of these factors are really unique to you.” - Dr. Kim Millman In this episode: - [01:25] - What does a high NTx mean, and what can you do about that? - [09:15] - If you break a leg and struggle for the bones to mend, what are the best bone-building foods, minerals, vitamins, herbs, and spices to help the bones heal? - [13:54] - I wasn't aware of the link between glucose level and bone loss. What are some strategies for lowering blood glucose other than reducing sweets and sweetened beverages? - [21:08] - For someone with a high CTX of 869, are there supplements that will help lower this number? - [22:29] - If you eat a spinach salad for lunch or overnight oats with chia seeds for breakfast, how long after the spinach salad or chia seeds should you wait to absorb the calcium from a glass of milk? - [23:54] - Success stories from people who eliminated oxalates from their diet [26:09] - Can you suggest the best collagen for bones? Is it important to buy organic collagen and to see “For the Bones” listed in the packet? - [27:22] - How do we get doctors to work with us to find root causes? What's the conversation like? I'm not having luck here. I feel like my current endocrinologist fired me because I'm refusing to take the drug treatment until I find out more about the cause. - [34:26] - Getting 1200 mg of calcium every day from food is very challenging. Is taking a 600mg supplement better than not meeting the 1200? Is it safe to take calcium supplements if you have kidney stones? Resources mentioned - Restore & Rebuild: 100 Days to Healthier Bones - https://themillmanclinic.com/randr?affiliate=mbissinger (Dr. Millman is giving the Happy Bones community a $100 off in addition to the early bird discount of $300. USE COUPON CODE HAPPYBONES24 FOR THE EXTRA $100 DISCOUNT.) - Happy Bones Membership - https://www.happyboneshappylife.com/bones-club More about Margie - Website - https://margiebissinger.com/ - Facebook - https://www.facebook.com/p/Margie-Bissinger-MS-PT-CHC-100063542905332/ - Instagram - https://www.instagram.com/margiebissinger/?hl=en DISCLAIMER – The information presented on this podcast should not be construed as medical advice. It is not intended to replace consultation with your physician or healthcare provider. The ideas shared on this podcast are the expressed opinions of the guests and do not always reflect those of Margie Bissinger and Happy Bones, Happy Life Podcast. *In compliance with the FTC guidelines, please assume the following about links on this site: Some of the links going to products are affiliate links of which I receive a small commission from sales of certain items, but the price is the same for you (sometimes, I even get to share a unique discount with you). If I post an affiliate link to a product, it is something that I personally use, support, and would recommend. I personally vet each and every product. My first priority is providing valuable information and resources to help you create positive changes in your health and bring more happiness into your life. I will only ever link to products or resources (affiliate or otherwise) that fit within this purpose.
In this episode, we sit down with Dr. John Neustadt, an expert in bone health, to unravel the complexities of maintaining strong bones throughout life. We delve into the often-overlooked aspects of bone health, beyond just bone mineral density, and explore the critical role of the extracellular matrix, hormones, and lifestyle choices in ensuring robust skeletal health.Key Highlights:The Real Impact of Bone Health: Understanding the staggering statistics of hip fractures and mortality in the elderly.Beyond Bone Density: Why bone mineral density tests don't tell the whole story and the importance of the extracellular matrix in bone health.The Dynamic Duo of Osteoblasts and Osteoclasts: How these cells regulate bone health by breaking down old bone and rebuilding new, healthy bone.Minerals and Hormones in Harmony: The vital role of calcium, magnesium, vitamin D, and parathyroid hormone in maintaining bone health.Bones as Signaling Tissues: Discover how bones contribute to overall health by stimulating various bodily functions.Innovative Testing for Bone Health: Exploring new tests like the CTX test for a more accurate prediction of bone health.Pediatric Concerns, Geriatric Consequences: The importance of addressing bone health early in life.Medication Watch: How certain medications like glucocorticoids, PPIs, and SSRIs can negatively impact bone health.Supplements for Bone Strength: The role of collagen, vitamin D, calcium, and vitamin K2 in reversing bone loss.Promising Therapies: A look at vibration therapy, cryotherapy, sauna, and PEMF therapy in improving bone health.Why Listen:This episode is a must-listen for anyone interested in a comprehensive understanding of bone health and longevity. Dr. Neustadt's insights offer a new perspective on how to approach bone health proactively, emphasizing the importance of early intervention, proper nutrition, and lifestyle modifications. Whether you're concerned about your bone health or looking to prevent future issues, this discussion provides valuable knowledge and practical tips.Check my website:https://www.acadianapain.com/resethttps://www.derrickhines.comFollow me on social at:https://www.tiktok.com/@drderrickhttps://www.instagram.com/derrickbhines
Osteoporosis is a common chronic disease, especially for people aged 50 and up. It is a silent disease, meaning it often has no symptoms. If you have osteoporosis, you are more likely to fracture or break a bone if you fall over. Everyone's bones become weaker as they age, but this process happens too quickly in some people. Women often rapidly lose bone after the onset of menopause. So, what can you do to protect your bones and prevent osteoporosis? In this special episode, I get interviewed by my husband, Dr. Craig Bissinger, about the exciting and new information I learned from over 50 health experts featured in the upcoming Natural Approaches to Osteoporosis and Bone Health Summit on January 15-21, 2024. Join the MORE Natural Approaches to Osteoporosis and Bone Health Summit Craig is an OB-GYN. We met in Chicago, and then he went to the East Coast with me. He then took a job with his partners for the past three decades and has worked at Morristown Medical Center ever since. Thanks for tuning in to another informative episode of the Happy Bones, Happy Life podcast! “What everybody can do is balance exercises. Typically, falls and fractures don't just happen. They happen because of a fall.” - Margie Bissinger In this episode: - [01:15] - Are there medications to treat osteoporosis? - [06:51] - What the CTX and P1NP tests reveal and why these tests are important - [10:30] - The interesting connection between exercise and osteoporosis - [17:48] - The benefit of pelvic floor physical therapy - [22:44] - Balance exercises to help prevent falls and fractures - [29:58] - Indigenous practices that help improve one's health and quality of life - [31:36] - Discovering the root cause of weak bones - [38:20] - What are oxalates, and why do people freak out about this topic? - [43:00] - Why should someone join the Osteoporosis and Bone Health Summit? Resources mentioned - MORE Natural Approaches to Osteoporosis and Bone Health Summit - Mastering Core Activation for Weight Training and Life with Dr. Claudia Tamas on January 4th Connect with Craig Bissinger, MD - Website More about Margie - Website - Facebook - Instagram DISCLAIMER – The information presented on this podcast should not be construed as medical advice. It is not intended to replace consultation with your physician or healthcare provider. The ideas shared on this podcast are the expressed opinions of the guests and do not always reflect those of Margie Bissinger and Happy Bones, Happy Life Podcast. *In compliance with the FTC guidelines, please assume the following about links on this site: Some of the links going to products are affiliate links of which I receive a small commission from sales of certain items, but the price is the same for you (sometimes, I even get to share a unique discount with you). If I post an affiliate link to a product, it is something that I personally use, support, and would recommend. I personally vet each and every product. My first priority is providing valuable information and resources to help you create positive changes in your health and bring more happiness into your life. I will only ever link to products or resources (affiliate or otherwise) that fit within this purpose.
ThursdAI TL;DR - November 23 TL;DR of all topics covered: * OpenAI Drama* Sam... there and back again. * Open Source LLMs * Intel finetuned Mistral and is on top of leaderboards with neural-chat-7B (Thread, HF, Github)* And trained on new Habana hardware! * Yi-34B Chat - 4-bit and 8-bit chat finetune for Yi-34 (Card, Demo)* Microsoft released Orca 2 - it's underwhelming (Thread from Eric, HF, Blog)* System2Attention - Uses LLM reasons to figure out what to attend to (Thread, Paper)* Lookahead decoding to speed up LLM inference by 2x (Lmsys blog, Github)* Big CO LLMs + APIs* Anthropic Claude 2.1 - 200K context, 2x less hallucinations, tool use finetune (Announcement, Blog, Ctx length analysis)* InflectionAI releases Inflection 2 (Announcement, Blog)* Bard can summarize youtube videos now * Vision* Video-LLaVa - open source video understanding (Github, demo)* Voice* OpenAI added voice for free accounts (Announcement) * 11Labs released speech to speech including intonations (Announcement, Demo)* Whisper.cpp - with OpenAI like drop in replacement API server (Announcement)* AI Art & Diffusion* Stable Video Diffusion - Stability releases text2video and img2video (Announcement, Try it)* Zip-Lora - combine diffusion LORAs together - Nataniel Ruiz (Annoucement, Blog)* Some folks are getting NERFs out from SVD (Stable Video Diffusion) (link)* LCM everywhere - In Krea, In Tl;Draw, in Fal, on Hugging Face* Tools* Screenshot-to-html (Thread, Github)Ctrl+Altman+Delete weekendIf you're subscribed to ThursdAI, then you most likely either know the full story of the crazy OpenAI weekend. Here's my super super quick summary (and if you want a full blow-by-blow coverage, Ben Tossel as a great one here)Sam got fired, Greg quit, Mira flipped then Ilya Flipped. Satya played some chess, there was an interim CEO for 54 hours, all employees sent hearts then signed a letter, neither of the 3 co-fouders are on the board anymore, Ilya's still there, company is aligned AF going into 24 and Satya is somehow a winner in all this.The biggest winner to me is open source folks, who got tons of interest suddenly, and specifically, everyone seems to converge on the OpenHermes 2.5 Mistral from Teknium (Nous Research) as the best model around! However, I want to shoutout the incredible cohesion that came out of the folks in OpenAI, I created a list of around 120 employees on X and all of them were basically aligned the whole weekend, from ❤️ sending to signing the letter, to showing how happy they are Sam and Greg are back! YayThis Week's Buzz from WandB (aka what I learned this week)As I'm still onboarding, the main things I've learned this week, is how transparent Weights & Biases is internally. During the whole OAI saga, Lukas the co-founder sent a long message in Slack, addressing the situation (after all, OpenAI is a big customer for W&B, GPT-4 was trained on W&B end to end) and answering questions about how this situation can affect us and the business. Additionally, another co-founder, Shawn Lewis shared a recording of his update to the BOD of WandB, about out progress on the product side. It's really really refreshing to see this information voluntarily shared with the company
날 ▶ 교사의 사망 2년만에 밝혀진 진실 지난 2021년 6월과 12월. 경기도 의정부시의 한 초등학교에서 초임교사 두 명이 스스로 생을 마감했다. 이후 학교 측은 교육청에 두 교사의 죽음을 모두 ‘추락사'라고만 보고했고, 이에 단순 사고사로 분류되었다. 학교는 물론 교육청까지 두 교사의 추가 조사는 진행하지 않았는데. 2023년 서이초등학교 교사 사망과 함께 교권 침해 문제가 불거지자 두 교사의 유가족들은 입을 열었다. 그중 이영승 선생님은 2016년부터 지속적인 학부모 민원에 시달린 사실이 공개되었다. 당시 수업 소중 페트병을 자르다 학생이 손가락을 다친 뒤 학부모가 교사에게 지속적으로 보상을 요구한 것. 이에 지난 21일 목요일. 경기도 교육청은 호원초 교사 사망사건에 대한 자체 감사 결과 이영승 교사에 대한 교육 활동 침해행위 사실이 확인되었다 공식 발표했다. 이후 도교육청은 이영승 교사의 교육 활동을 침해한 학부모 3명을 업무방해 혐의로 의정부 경찰서에 수사를 의뢰한 상태. 호원초 사건 이후 사적 제제 문제도 붉어지고 있다. SNS를 통해 학부모의 신원과 직장, 당시 학생이었던 자녀의 학교까지 무분별하게 정보가 쏟아지고 있는 것. 유가족 대리인은 개인적인 신상 공개를 유가족은 물론 사회적 위험성을 초래할 수 있어 자제해달라고 당부하는데. 사라지지 않는 학부모 악성 민원에 병들고 있는 교권. 계속되고 있는 피해를 에서 취재했다. 밀착카메라 24시 ▶ 추석 앞두고 원산지 표시 위반 기승 지난 주, 추석을 앞두고 미국산 냉동 쇠고기를 한우로 둔갑시켜 판매한 업체들이 덜미를 잡혔다. 식품안전관리인증기준 인증을 받지 않은 한 식육 가공업체. 훈제족발, 훈제 삼겹살을 가공한 후 불법으로 인증표시를 부착해 급식소와 식당 등에 납품한 것이 적발됐다. 해당 업체는 최근 2개월간 불법행위로 2억 7000만 원의 매출을 올렸는데. 이에 전북지역 농산물품질관리원 기동대원들이 집중 단속에 나섰다. 전통시장, 음식점, 식자재 마트 등 추석 선물 제수용품의 농축산물 원산지 위반 사항을 집중적으로 살펴봤는데. 축산물 이력번호 미기재 및 허위기재, 거래 내역서 작성 이행 여부 등 원산지 표기와 관련해 수십 건이 적발됐다. 최근 배달 앱이나 온라인 거래 또한 증가한 가운데 농축산물 원산지 미표시 등 위반 행위가 끊이지 않고 있어 사각지대는 계속해서 발생하는 상황. 추석 명절을 앞두고 원산지 표시 위반이 기승하는 그 현장을
El Ford Fiesta nació en 1976. Y 12 millones de unidades vendidas más tarde han muerto antes de lo esperado, no ha llegado ni siquiera al 2024, ha sido en 2023… Vale la pena hacer un repaso a la historia de este modelo y a los motivos de su prematuro, y para muchos indeseado, fallecimiento. Y es que el Fiesta a lo largo de 7 generaciones ha sido un coche, para muchos, de “toda la vida”. Un coche que, en Europa y sobre todo en España, revolucionó su segmento, un coche con unas versiones básicas muy interesantes y unos modelos deportivos de un atractivo excepcional… Yo he tenido uno de cada. Pero ha sido una muerte a tres manos: La agenda 2030, los SUV y los híbridos han acabado con nuestro querido Ford Fiesta. ¿Una muestra de lo que quieren los consumidores? ¿O una muestra de lo que quieren las marcas? Los “nuevos” utilitarios. Ya desde 1975 las revistas de coches, de las que era lector compulsivo, ya hablaban del Ford “pequeño”, pero no del Fiesta, sino del Bobcat, que era el nombre clave para este coche. Y es que en esos años los Fiat-Seat 127 y los Renault 5 arrasaban en Europa, sobre todo en el sur de Europa. Y Ford quería parte de ese apetitoso bocado. El departamento de marketing de la marca propuso muchos nombres, casi todos cos raíces latinas: Amigo, Bambi, Bebe, Bolero, Bravo, Chico, Fiesta, Forito, Metro, Pony, Sierra y Tempo entre otros. Por votación se eligió el de “Bravo", que luego usaría Fiat, pero ¿sabéis las leyes del jefe? Henry Ford II dijo que Fiesta… y no hubo nada que hablar… para mí, acertó. Coche nuevo, fábrica nueva. Este coche se fabricó en muchos lugares, entre ellos Dagenham, en el Reino Unido y Colonia, en Alemania. Pero para los españoles este coche tuvo algo muy especial: Se construyó una fábrica de nueva planta, muy moderna, en la localidad de Almussafes, provincia de Valencia. Primera generación (1976-1983). En 1976 los Fiat-Seat 127 y sobre todos los R5 ofrecían y buen nivel de acabado… pero el Fiesta, desde sus comienzos, estaba a otro nivel. Por prestaciones no estaba al nivel del 127, por confort quizás se colocaba algo por detrás del R5, pero por calidad de terminación, acabado y equipamiento, les superaba… y, por cierto, en lo que respecta a habitabilidad. Hay que nombrar dos referentes del momento, el Ford Fiesta 1.300 Super Sport, de anchísimas ruedas y sobre todo el XR2 como motor 1.6 y 84 CV de potencia para apenas 800 kg. Segunda generación (1983-1989). En realidad, fue una modernización del primer Fiesta a base de redondear sobre todo la parte delantera. Honestamente, no me pareció un “restyling” muy logrado. En esta generación hay dos hitos, el cambio de variación continua CTX que pude probar en el Reino Unido y el nuevo XR2 con motor ya de 96 CV. Tercera generación (1989-1995). Algunos, por ejemplo “Wikipedia” llaman a esta generación la segunda generación FASE 1. Bueno, yo prefiero la tercera. Tuve un XR2 de inyección que ya llegaba a los 110 CV, pero un coche con un defecto, común en esos tiempos: Podías elegir o servodirección o A/A, ambas cosas no. Y la dirección mecánica era muy dura… ¡y con 4 vueltas de volante! Aparece la versión RS Turbo de 133 CV… un coche que levantó polémicas en su momento. Cuarta generación (1995-2002). Para mí, de lejos, el Fiesta más feo que haya existido. O el menos bonito. Lo más importante de esta generación es la aparición de nuevos y buenos motores, los Zetec de gasolina de 16v, en cilindrada de 1.2, 75 CV, 1.4 y 90 CV. Sin olvidar los turbodiésel con hasta 75 CV. Quinta generación (2002-2008). Muchos llaman a los Ford Fiesta fabricados a partir de 2002 tercera generación, por ejemplo Wikipedia. Y tiene sentido porque lo cierto es que hasta 2002 las sucesivas evoluciones del Fiesta eran estéticas y de mecánica, pero el bastidor evolucionó poco. Pero en esta sí que evolucionó y el coche creció.Y además aparece otra denominación mítica: El Fiesta ST. Sexta generación (2008-2017). Lo más interesante de este “Forfi” era que compartía plataforma con el Mazda 2… eran los momentos dulces de la relación de ambas marcas. El coche crece en tamaño, en oferta, en mercados… pero sin ser ni mucho menos feo, no dejada de ser una especie de Focus “pequeñito” que no a todo el mundo gustaba. Séptima generación (2017-2023). Siempre se dice que los coches mueren cuando son mejores. Y esto en el caso del Ford Fiesta se cumple a rajatabla. El último Fiesta es bonito, bien acabado, con buenas motorizaciones. Sí, sé lo que estás pensando, en el motor tricilíndrico de 1.0 litros Ecobost con Turbo y 125 CV. ¿Por qué se muere el Ford Fiesta? Hay teorías para todo. Ya hemos hablado de los SUV, los eléctricos e híbridos, la agenda 2030… no hemos hablado del éxito del Puma, un nombre rescatado de un deportivo para aplicarlo a un SUV… así son los tiempos que vivimos.
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.06.20.545791v1?rss=1 Authors: Simpson, M. S., De Luca, H., Cauthorn, S., Luong, P., Udeshi, N., Svinkina, T., Schmeider, S. S., Carr, S. A., Grey, M. J., Lencer, W. I. Abstract: IRE1 is an endoplasmic reticulum sensor that recognizes misfolded proteins to activate the unfolded protein response (UPR). We used cholera toxin (CTx), which activates IRE1 in cells, to understand how unfolded proteins are recognized. In vitro, the A1 subunit of CTx (CTxA1) bound IRE1 lumenal domain (IRE1LD). Global unfolding was not required. Instead, IRE1LD recognized a 7-residue motif within a metastable region of CTxA1 that was also found in microbial and host proteins involved in IRE1 activation. Binding mapped to a pocket on IRE1LD normally occupied by a segment of the IRE1 C-terminal flexible loop implicated in IRE1 regulation. Mutation of the recognition motif blocked CTx-induced IRE1 activation in live cells. These findings describe a mechanism for substrate recognition by IRE1 that induces the UPR. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC
Part 2 of a thorough conversation with Don Christian allowing response on behalf of CTX to many accusations or confusions heading into the Synod Convention. Don and CTX have issued a response to the report, but it is often best to hear what is said, not just what is written.Visit uniteleadership.org
Listen to Dr. Sandy Kirk at our CTX 2023 Area Aglow Conference as she shares a word on "Give Jesus The Reward of His Suffering!
Dr. R. Keith McCormick is a chiropractic physician specializing in the management of patients with osteoporosis. He is the author of the recently released book – Great Bones: Taking Control of Your Osteoporosis and The Whole Body Approach to Osteoporosis. Sports have always played a vital part in Dr. McCormick's life. He is the former U.S. record holder for the most points scored in a pentathlon competition. Dr. McCormick continues to compete in triathlons of all distances and has completed six Ironman competitions, five of them after recovering from multiple osteoporosis-related fractures. In this episode, Dr. McCormick discusses the role of bone turnover markers in the management of osteoporosis. Unfortunately, these tests are underutilized and they can give us so much important information. You don't want to miss this enlightening interview. Links Great Bones: Taking Control of Your Osteoporosis Also on Amazon Dr. McCormick's Website Improve Your Bone Health Naturally Mini-Class (free resource!) Timestamps [02:43] Bone Markers [09:35] How Soon To Do a Repeat Test [18:15] What Units Will You See When Looking at CTX [26:05] People with Different Root Causes [42:50] Want to Take a Deeper Dive? Here's What's Available DISCLAIMER – The information presented on this podcast should not be construed as medical advice. It is not intended to replace consultation with your physician or healthcare provider. The ideas shared on this podcast are the expressed opinions of the guests and do not always reflect those of Margie Bissinger and Happy Bones, Happy Life Podcast.
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.01.26.525630v1?rss=1 Authors: Caron, D., Buccelli, S., Canal-Alonso, A., Hernandez, M., Pruzzo, G., Corchado, J. M., Chiappalone, M., Panuccio, G. Abstract: Hippocampal dysfunction is the hallmark of mesial temporal lobe epilepsy (MTLE), the most common epileptic syndrome in adults and the most often refractory to medical therapy. Deep brain stimulation (DBS) may ameliorate drug-refractory MTLE, but it still cannot guarantee a seizure-free life. One major drawback is that the stimulation policy is informed by trial-and-error rather than by the operating mode of the brain. Thus, optimizing DBS parameters is still an unmet clinical need. Here, we propose the deployment of hippocampal interictal activity in a biohybrid approach to control limbic ictogenesis. Specifically, an electronic bridge establishes a graft-host interaction between the hippocampal subfield CA3 (graft) and the parahippocampal cortex (CTX - host) of distinct rodent brain slices, both treated with 4-aminopyridine; the electronic bridge relays the graft interictal events to the host via electrical pulses. We show that interictal activity generated by the graft CA3 controls limbic ictogenesis in the host CTX even in the absence of feedback from it, thus likely reflecting an intrinsic anti-ictogenic clock of this brain region. This work opens a translational perspective for MTLE treatment via biohybrid neuroprostheses relying on the intrinsic clock of incorporated hippocampal cells. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC
VIDEOS: Dem Party Turns On Anti-War Democratic Primary Winner (2:16 to 5:28) Society is going to COLLAPSE -Neil Oliver ( 5:24) Fear Psychosis and the Cult of Safety – Why are People so Afraid? – Academy of Ideas (13:25) The Great Reset and Transhumanism | Beyond the Cover (17:50) Zinc supplementation associated with higher levels of brain growth factor Soybean foods may protect menopausal women against osteoporosis Study finds diet high in saturated fat can reprogram immune cells in mice Coenzyme Q10 consumption reverses cholesterol transport Study confirms that processed foods key to rising obesity Violence on TV: Effects from age 3 can stretch into the teen years Zinc supplementation associated with higher levels of brain growth factor Iran University of Medical Sciences, November 4 2022. A review and meta-analysis of randomized, controlled trials affirmed an association between supplementing with zinc and higher circulating levels of brain-derived neurotrophic factor (BDNF). Brain-derived neurotrophic factor plays a positive role in the survival of brain cells known as neurons. A reduction in BDNF expression occurs in Alzheimer and Parkinson diseases, multiple sclerosis and amyotrophic lateral sclerosis. Antidepressants and anthocyanin supplements have been shown to increase BDNF gene expression, and serum or plasma levels have been elevated by exercise and omega-3 fatty acid, resveratrol or zinc supplementation. For their review and meta-analysis, Fahimeh Agh of Iran University of Medical Sciences and colleagues identified four trials that evaluated the effects of zinc supplements on serum or plasma BDNF levels among 185. Zinc dosages ranged from 25–30 milligrams per day given for 84–90 days. Pooled results of the trials found significantly higher BDNF levels among participants who received zinc compared with participants in the control groups. The increase in BDNF was significant at 30 milligram doses (which were used in 3 trials) and at all trial durations. Among the 3 trials that analyzed serum zinc levels, participants who were given zinc supplements had significantly increased zinc levels in comparison with the control participants. “A large body of evidence indicated BDNF as an important predictive factor for following the beginning, progress and cure of brain disorders due to its main role in brain neurogenesis and neuroplasticity,” Agh and her associates wrote. “Increased circulating levels of BDNF as a result of zinc supplementation suggest that zinc supplementation may be a safe and effective strategy to counteract neurodegenerative diseases that are correlated with low BDNF levels,” they concluded. Soybean foods may protect menopausal women against osteoporosis University of Hull (UK), November 1, 2022 Eating a diet rich in both soy protein and isoflavones can protect menopausal women from bone weakening and osteoporosis, according to the results of a preliminary study presented today at the Society for Endocrinology annual conference in Edinburgh. Soybean foods contain chemicals known as isoflavones that are similar in structure to oestrogen and so could theoretically protect women against osteoporosis by mimicking the action of oestrogen. In this study, researchers from the University of Hull gave two hundred women in early menopause a daily supplement containing soy protein with 66mg of isoflavones or a supplement with soy protein alone for six months. The researchers investigated changes in the women's bone activity by measuring certain proteins (βCTX and P1NP) in their blood. They found that the women on the soy diet with isoflavones had significantly lower levels of βCTX than the women on soy alone, suggesting that their rate of bone loss was slowing down and lowering their risk of developing osteoporosis. Women taking soy protein with isoflavones were also found to have decreased risk of cardiovascular disease than those taking soy alone. “The 66 mg of isoflavone that we use in this study is equivalent to eating an oriental diet, which is rich in soy foods. In contrast, we only get around 2-16 mg of isoflavone with the average western diet.” “Supplementing our food with isoflavones could lead to a significant decrease in the number of women being diagnosed with osteoporosis.” Study finds diet high in saturated fat can reprogram immune cells in mice Portland State University, November 7, 2022 A new study by Portland State University researchers is the first to show that eating a diet exclusively high in saturated fats can reprogram the mouse immune system, making it better able to fight off infection but more susceptible to systemic inflammatory conditions, including sepsis. Brooke Napier, assistant professor of biology at PSU, led the study, which was published in eLife. The ketogenic or “keto” diet is a popular high-fat diet used for weight loss or to control epileptic seizures. This study shows that when mice eat a ketogenic diet that is high in saturated fats it can have a significant impact on their immune system. A previous study by Napier and colleagues found that mice fed a high-fat, high-sugar Western diet were more susceptible to sepsis and had a higher mortality rate than mice fed a standard diet. In the current study, the researchers found similar effects in mice fed a high-fat ketogenic diet, suggesting that dietary fat may play a role in sepsis. The researchers focused on one particular fat found in the blood of the mice fed a ketogenic diet: palmitic acid, which is commonly found in animal fats and dairy products. Remarkably, mice fed a normal diet who were injected with palmitic acid also became more susceptible to sepsis. “It was just exposure to this one saturated fat that made them more susceptible to sepsis mortality,” says Napier. “The idea that you could have a specific fat in your diet that would cause such a drastic outcome in disease is kind of incredible.” Napier and her team next probed just how exactly high levels of palmitic acid could initiate sepsis. Their first clue came when they noticed that mice fed the Western diet, mice fed the ketogenic diet, and mice treated with palmitic acid all had high levels of inflammatory cytokines, immunological hormones that can cause fever and systemic inflammation during sepsis. The presence of the inflammatory cytokines suggested that palmitic acid could be affecting the immune system by causing inflammation, but Napier soon discovered that the story was more complicated—and more interesting—than that. Napier and colleagues also found that another type of fat may be able to counteract the harmful effects of palmitic acid. Oleic acid, a polyunsaturated fat found in many plant-based oils including olive oil, can block the synthesis of ceramide, a fatty substance that can initiate a stress response in cells and may play a role in the hyperinflammatory response that causes sepsis. When the researchers fed mice a ketogenic diet for two weeks but also gave them oleic acid for the final three days, they no longer showed an increased susceptibility to sepsis. Coenzyme Q10 consumption reverses cholesterol transport Sun Yat Sen University (Taiwan), October 31, 2022 According to news reporting out of Guangdong, People's Republic of China, research stated, “We have recently shown that coenzyme Q10 (CoQ10) enhances macrophage reverse cholesterol transport via activator protein-1/miRNA-378/ABCG1 signal pathway in vivo and in vitro. Whether CoQ10 exerts similar beneficial effects in human is currently unknown.” Our news journalists obtained a quote from the research from Sun Yat Sen University, “The present study evaluated the effect of CoQ10 on ABCG1-mediated macrophage cholesterol efflux in 20 healthy volunteers. Participants were given 100 mg CoQ10 twice daily or placebo for 1 week with a 1-week washout period. Human monocyte-derived macrophages (MDMs) were differentiated under pooled sera obtained before (preCoQ10) or after CoQ10 (postCoQ10) consumption. The CoQ10-induced inhibition of MDMs foam cell formation was blocked by ABCG1 silencing in postCoQ10 MDMs incubated with postCoQ10 sera compared to preCoQ10 sera. The cholesterol efflux to HDL, and mRNA as well as protein expressions of ATP-binding cassette transporter G1 (ABCG1) were augmented in postCoQ10 MDMs incubated with postCoQ10 sera compared to preCoQ10 sera. The change in the serum CoQ10 concentration positively correlated with cholesterol efflux to HDL and ABCG1 mRNA level in the CoQ10 group. MDMs treated with purified CoQ10 had an enhanced cholesterol efflux to HDL.” According to the news editors, the research concluded: “CoQ10 consumption may have an atheroprotective property by inducing ABCG1 expression and enhancing HDL-mediated macrophage cholesterol efflux in healthyindividuals.” Study confirms that processed foods key to rising obesity University of Sydney (Australia), November 7, 2022 A year-long study of the dietary habits of 9,341 Australians has backed growing evidence that highly processed and refined foods are the leading contributor of rising obesity rates in the Western world. “As people consume more junk foods or highly processed and refined foods, they dilute their dietary protein and increase their risk of being overweight and obese, which we know increases the risk of chronic disease,” said lead author Dr. Amanda Grech, a Postdoctoral Research Fellow at the CPC and the university's School of Life and Environmental Sciences. “It's increasingly clear that our bodies eat to satisfy a protein target,” added Professor David Raubenheimer, the Leonard Ullmann Chair in Nutritional Ecology at the School of Life and Environmental Sciences. “But the problem is that the food in Western diets has increasingly less protein. So, you have to consume more of it to reach your protein target, which effectively elevates your daily energy intake. The University of Sydney scientists analyzed data from a cross-sectional survey of nutrition and physical activity in 9,341 adults, known as the National Nutrition and Physical Activity Survey with a mean age of 46.3 years. They found the population's mean energy intake was 8,671 kilojoules (kJ), with the mean percentage of energy from protein being just 18.4 percent, compared with 43.5 percent from carbohydrates and from 30.9 percent from fat, and just 2.2 percent from fiber and 4.3 percent from alcohol. They also found a statistically significant difference between groups by the third meal of the day: those with a higher proportion of energy from protein at the start of the day had much lower total energy intake for the day. Meanwhile, those who consumed foods low in protein at the start of the day proceeded to increase consumption, indicating they were seeking to compensate with a higher consumption of overall energy. This is despite the fact the first meal was the smallest for both groups, with the least amount of energy and food consumed, whereas the last meal was the largest. Participants with a lower proportion of protein than recommended at the first meal consumed more discretionary foods—energy-dense foods high in saturated fats, sugars, salt, or alcohol—throughout the day, and less of the recommended five food groups (grains; vegetables/legumes; fruit; dairy and meats). Consequently, they had an overall poorer diet at each mealtime, with their percentage of protein energy decreasing even as their discretionary food intake rose—an effect the scientists call ‘protein dilution'. While many factors contribute to excess weight gain—including eating patterns, physical activity levels, and sleep routines—the University of Sydney scientists argue the body's powerful demand for protein, and its lack in highly processed and refined foods, is a key driver of energy overconsumption and obesity in the Western world. Violence on TV: Effects from age 3 can stretch into the teen years University of Montreal, November 7, 2022 Watching violent TV during the preschool years can lead to later risks of psychological and academic impairment by the summer before middle school starts, according to a new study led by Linda Pagani, a professor at Université de Montréal's School of Psycho-Education. Before now, “it was unclear to what extent exposure to typical violent screen content in early childhood—a particularly critical time in brain development—can predict later psychological distress and academic risks,” said Pagani. “The detection of early modifiable factors that influence a child's later well-being is an important target for individual and community health initiatives, and psychological adjustment and academic motivation are essential elements in the successful transition to adolescence,” she added. “So, we wanted to see the long-term effect of typical violent screen exposure in preschoolers on normal development, based on several key indicators of youth adjustment at age 12.” To do this, Pagani and her team examined the violent screen content that parents reported their children viewing between ages 3 1/2 and 4 1/2, and then conducted a follow-up when the children reached age 12. “Compared to their same-sex peers who were not exposed to violent screen content, boys and girls who were exposed to typical violent content on television were more likely to experience subsequent increases in emotional distress,” said Pagani. “They also experienced decreases in classroom engagement, academic achievement and academic motivation by the end of the sixth grade,” she added. “For youth, transition to middle school already represents a crucial stage in their development as adolescents. Feeling sadness and anxiety and being at risk academically tends to complicate their situation.” In all, the parents of 978 girls and 998 boys participated in the study of violent TV viewing at the preschool age. At age 12 years, the children and their teachers rated the children's psychosocial and academic achievement, motivation and participation in classroom activities. “Preschool children tend to identify with characters on TV and treat everything they see as real,” Pagani said. “They are especially vulnerable to humorous depictions of glorified heroes and villains who use violence as a justified means to solve problems. “Repeated exposure,” she added, “to rapidly paced, adrenaline-inducing action sequences and captivating special effects could reinforce beliefs, attitudes and impressions that habitual violence in social interactions is ‘normal.' Mislearning essential social skills can make it difficult to fit in at school.” Added Bernard, “Just like witnessing violence in real life, being repeatedly exposed to a hostile and violent world populated by sometimes grotesque-looking creatures could trigger fear and stress and lead these children to perceive society as dangerous and frightening. And this can lead to habitually overreacting in ambiguous social situations. In the preschool years, the number of hours in a day is limited, and the more children get exposed to aggressive interactions (on screens) the more they might think it normal to behave that way.”
Chris was born in El Paso, TX, ultimately becoming a military brat that got stuck in Central Texas. He has been in the comedy game for almost 2 years, doing open mics and showcases all around CTX and even a few in Georgia! Chris says that he got into comedy because he sucks at everything, but he can sure tell a joke! His ultimate comedy goal is to be on the road, making a living traveling and making people laugh all over the country and eventually the world. Chris has a passion for performing and the drive to see his passion become his reality. Instagram.com/theonlytipher www.youtube.com/channel/UCXgtk7T7D5vspwS9ed2fxlA Theme Song: Knif.es
On this week's show Patrick Gray and Adam Boileau discuss the week's security news, including: The msdt/office lolbinapalooza Microsoft to introduce sensible defaults to Azure Twitter fined $150m for sms 2fa spam It turns out npm got owned in that Heroku/Travis CI thing AWS cred-stealing supply chain attack was research your honour, I swear! Much, much more We'll be chatting with Airlock Digital co-founder and CTO Daniel Schell in this week's sponsor interview. He'll be walking us through some of his own research into how to own Microsoft boxes via document-embedded office add-ins. Links to everything that we discussed are below and you can follow Patrick or Adam on Twitter if that's your thing. Show notes nao_sec on Twitter: "Interesting maldoc was submitted from Belarus. It uses Word's external link to load the HTML and then uses the "ms-msdt" scheme to execute PowerShell code. https://t.co/hTdAfHOUx3 https://t.co/rVSb02ZTwt" / Twitter Follina — a Microsoft Office code execution vulnerability | by Kevin Beaumont | May, 2022 | DoublePulsar Kevin Beaumont on Twitter: "Additional Follina issue, if you use wget in Powershell, it blindly executes any code via MSDT as it trusts all MS Protocol URIs. So to clarify, if you wget a webpage you don't control and the webpage adds Follina exploit string, your server the runs the code." / Twitter Microsoft Office Remote Code Execution - “Follina” MSDT Attack Raising the Baseline Security for all Organizations in the World - Microsoft Tech Community npm security update: Attack campaign using stolen OAuth tokens | The GitHub Blog Twitter fined $150 million by FTC for alleged privacy violations - The Record by Recorded Future REvil prosecutions reach a 'dead end,' Russian media reports Multiple flights across India grounded after SpiceJet airline hit with ransomware - The Record by Recorded Future Exclusive: Russian hackers are linked to new Brexit leak website, Google says | Reuters Российские компании начали увольнять украинских ИT-специалистов — РБК Hacker Leaks Mountain of Files From Inside Xinjiang Camps Spain set to strengthen oversight of secret services after NSO spying scandal | The Times of Israel No evidence of exploitation of Dominion voting machine flaws, CISA finds - The Washington Post Researchers identify FIDO2 protocol vulnerabilities - Security - iTnews 756.pdf Security ‘researcher' hits back against claims of malicious CTX file uploads | The Daily Swig Israeli private detective used Indian hackers in job for Russian oligarchs, court filing says | Reuters Hacker Steals Database of Hundreds of Verizon Employees GarWarner on Twitter: "Last month the US Department of Justice petitioned the court to be allowed to seize Mr. Woodbery's Bitcoin. 151.885720427 BTC is 11,930,370 Naira or $4,364,299 USD currently. (Thread 1/? ) https://t.co/Xh39FTLQUV" / Twitter Malcolm Herbert on Twitter: "@riskybusiness @Metlstorm ... for some reason I never pictured you guys as doing a recording session before sunup, but then I guess with @Metlstorm being in NZ that kinda makes sense now that I think about it ... I'll see myself out ..." / Twitter Darknet market Versus shuts down after hacker leaks security flaw Omnipotent BMCs from Quanta remain vulnerable to critical Pantsdown threat | Ars Technica Red Canary Managed Detection and Response - YouTube Airlock Digital Demo - YouTube
![Day[0] - Zero Days for Day Zero](https://ivyfm.s3.amazonaws.com/i320/820071.jpg)
Links and vulnerability summaries for this episode are available at: https://dayzerosec.com/podcast/a-zoom-rce-vmware-auth-bypass-and-gitlab-stored-xss.html Last bounty episode before our summer vacation, and we are ending off with some cool issues. XML Stanza smuggling in Zoom for a MitM attack, an odd auth bypass, a Gitlab Stored XSS and gadget based CSP bypass, and an interesting technique to leverage a path traversal/desync against NGINX Plus [00:01:00] How I hacked CTX and PHPass Modules [00:10:55] [Zoom] Remote Code Execution with XMPP Stanza Smuggling [00:19:38] VMware Authentication Bypass Vulnerability [CVE-2022-22972] [00:23:05] Breaking Reverse Proxy Parser Logic [00:26:44] [GitLab] Stored XSS in Notes (with CSP bypass) [00:37:13] GhostTouch: Targeted Attacks on Touchscreens without Physical Touch [00:48:00] Resources While We Are Gone The DAY[0] Podcast episodes are streamed live on Twitch (@dayzerosec) twice a week: Mondays at 3:00pm Eastern (Boston) we focus on web and more bug bounty style vulnerabilities Tuesdays at 7:00pm Eastern (Boston) we focus on lower-level vulnerabilities and exploits. The Video archive can be found on our Youtube channel: https://www.youtube.com/c/dayzerosec You can also join our discord: https://discord.gg/daTxTK9 Or follow us on Twitter (@dayzerosec) to know when new releases are coming.
[OIKAISU] Mörön ja Mirkun instagram-tili onkin oikeasti tämähttps://www.instagram.com/morko_and_mirkku_fieldies/Hand Tool Rescue YouTubessahttps://www.youtube.com/channel/UCasG9kJWi1eVxM0QkyqKVJQPythonin ctx-kirjasto haxoroituhttps://twitter.com/s0md3v/status/1529005758540808192https://isc.sans.edu/forums/diary/ctx+Python+Library+Updated+with+Extra+Features/28678/Kyberhyökkäykset eivät ole lisääntyneet Suomessahttps://yle.fi/uutiset/3-12461321Venäjällä APT-toimintaa Kiinan toimesta?https://securityaffairs.co/wordpress/131658/apt/unknown-apt-group-target-russia.htmlhttps://blog.malwarebytes.com/malwarebytes-news/2022/05/unknown-apt-group-has-targeted-russia-repeatedly-since-ukraine-invasion/amp/Twitterille sakot käyttäjätietojen väärinkäytöstähttps://arstechnica.com/tech-policy/2022/05/twitter-pays-150m-fine-for-using-two-factor-login-details-to-target-ads/Konglomeraattihttps://www.geologia.fi/glossary/konglomeraatti/
In today's podcast we cover four crucial cyber and technology topics, including: 1.Zoom updates to address four flaws that could allow remote code execution 2.Python libraries updated with malicious code to steal AWS information 3.Trend Micro pushes fix to address Chinese DLL hijacking of products 4.Malwarebytes finds new Chinese APT targeting Russian government I'd love feedback, feel free to send your comments and feedback to | cyberandtechwithmike@gmail.com
Subscribe to Benzinga Options NewsletterEpisode Summary:Coinbase $COIN drops on disappointing earnings reportAdding new stocks to our watchlist Buy or sell: LiveNation LYVGuests:Saagar Govil CEO of Cemtrex (Ticker: CETX) Greg Crawford CEO of Quipt $QIPT Jesse Kaylor, Elite TradingNic Chahine, author of the Benzinga Options NewsletterHosts:Spencer IsraelTwitter: https://twitter.com/sjisraelAaaron BryTwitter: https://twitter.com/aaronbry5Subscribe to all Benzinga Podcasts hereClick here for BENZINGA TRADING SCHOOL Get 20% off Benzinga PRO here Become a BENZINGA AFFILIATE and earn 30% on new subscriptionsDisclaimer: All of the information, material, and/or content contained in this program is for informational purposes only. Investing in stocks, options, and futures is risky and not suitable for all investors. Please consult your own independent financial adviser before making any investment decisions.Unedited TranscriptCan you hear us? Why are we running away to AB that is a great question. I don't understand. I, so one of our, our colleagues, Adam Partridge brought in a big bag of Halloween candy that was left over from his house. I was enamored by the bag and just go in through it. Um, but yeah, uh, Brohan had to physically dragged me away from the candy, but now I am here.So without further ado, let's go ahead and get this show. Rolling. Bren says you could get hurt. You could hear me before. Great.CEO, Jason. Razak here with us. The man, the myth, the legend Skeeter shifts on the power hour with us live today. Interesting different innovative company. You are alive.we need a new intro. AB can we get a new intro? Yep. W w we'll get working on that. Spencer's we've got a jam packed show today. Uh, do you want to give us a rundown of our agenda for the day? Oh yes, I can do that because I wrote stuff down. Uh, we've got our first gas coming up in seven minutes at 12, 15 Eastern time.Cigar global, the CEO of Centrix. Did I get that right? Yep. Okay. I just want to help you get out of the right seminars. Tickers seeds DX will be on at 1215, uh, Lena Alena, chin, head of IRR at newborn town at 1230. Uh, the CEO of quipped, Greg Crawford at 1245, Jesse Kaler from elite trading at one. And then Nick Shaheen from the author of the big thing, the options newsletter will be on the show at one 30.We got a lot to talk about today. Let's start with, you know, I don't know. Where do you want to start? AB well, places I want to start, um, let's start with a nice little crypto update. Spencer's so as many of you may know. Bitcoin hit a brand new, all time high today. This was spurred by the CPI data that came out this morning.So CPI came in hotter than expected showing, um, inflation and investors went and rushed to buy Bitcoin as an inflation hedge. So we had Bitcoin, uh, almost reach up to 69,000 up about 3.2, 6%. A theorem is up 2.14% nearing 5,000. So I'm looking for that as a big psychological level. Spencer, when a theory, um, hits 5,000, um, Shiba, Inu, and doge coin to dog related cryptocurrencies are down today in this sea of green.So maybe that's showing that investors are leaving Sheba and dos to go buy Ethereum and Bitcoin. I don't know. Um, but overall good day for crypto so far, we will continue to watch crypto and see how it's performing today. Um, but since there's other stuff in the news, I want to talk about before we move on, though, I just want to mention, you can get some free Bitcoin ha.Look at the screen, it says it right there. Go to Voyager, go to the app on your mobile device of your choice, whether to Android or iPhone or some other third OSTP, I'm not aware of down on the Voyager app in the app store, fund your account with a hundred bucks, make your first trade, and they'll give you $50 in BTC.You should do it before Bitcoin goes to a million. I'm just saying that because then you'll be getting more bang for your buck, but that's just me. Okay. I know you have things on your mind today, Aaron. Yes, I do have things on my mind before we get to that though. I want to introduce a new little game noodle segment.We have a new segment. Yeah. If you're like me and you grew up watching Pokemon as a kid, you know that the show used to do a thing called guests, that Pokemon, where they would give you the outline of a Pokemon. And you had to guess which one it was his name. Fine. You're right. It was named that Pokemon.So we're going to do that with charts, name, that chart. This is the first one we're going to do. I'm going to go ahead and pull it up on screen. Uh, as you can see, this is a recent, uh, not, I, I have, again, I, this is an easy one. Yeah. We're going to start. We're going to, uh, well, it could be one of, one of several actually.Um, and I don't know the answer can, so can, I guess AB you can guess this is a, this is an easy one. We're just going to start off easy and get more difficult as we do more iterations of this game. Oh, wait. I was not looking at the, the, the x-axis this, so this was from my high was October of last year. Oh yeah.Chris, who's that Pokemon? That's the correct one. No, no, I'll wait. No, no. Wait, how, how far back does this chart out? Exactly. It goes further back then. Uh, wait, are we looking at that? That's October 20th of this year, correct? Uh, Cobra flash. Okay. I don't know why I thought that. Um, okay. Yes, the answer is on the shadow.I would guess Brenda. Got it. Is what I'm thinking. Um, my guess is the same as his DW AAC, are we right? Yes. You are D whack right up $49 in the past month. Um, of course this was a spec, so it was trading around $10 for a very long time. And then once the merger was announced, the stock ran all the way up to about $170 before coming back down, currently trading right at $60.Um, so congrats to Brenda who was the first correct? Guests are in the chat with D whack. Um, you know, we, we are going to do this more often, so we'll introduce, we have to give away prizes to bring saw was in the chat. We got to give away some schwag. I think Brent is right. Email us shows that bends and good.com.I will get you hooked up with some free swag. Um, you know, maybe you pick out a hat or a t-shirt, but we will do this more. I will, uh, say the charts will get more difficult. So we started you off easy, but Brenda, don't, don't get used to getting such easy charts. Uh, yeah, that was a surprisingly easy one.And maybe next time I'll do it and there'll be some totally obscure stop. Yeah, that barely trades. Okay. Wait, we got two minutes before first guests are running behind here. I know you have a rant like in your city. That, uh, even you've been talking to me about this stock today. Do you want to go get that out there now?Or do you want, wait, yeah. Wait, we've only got a couple minutes, so let me just share my Benzing a pro I'll get it pulled up. Um, you're right, Spencer. This has been on my mind. So I've been watching live nation's stock, um, all week. And so live nation, of course, uh, the company that put on the, the Travis Scott concert that tragically ended, uh, with eight deaths.And I've just been surprised that we haven't seen this stock, um, trade. I know necessarily the markets don't really care about that, but there've been about 30 lawsuits opened up against live nation and the company has a history of. Uh, safety problems in past concerts. Not only that, but Travis, Scott has a history of having safety problems in past concerts.So for live nation, as a company to know we've had safety issues and Travis Scott who's at safety issues to not, um, do a better job of making sure, you know, all the, all the concert attendees were safe, taken care of. I mean, to me, that's just a big oversight, so we'll see. And in due time, what the outcome is of these lawsuits filed against live nation.Uh, but to me, I'm surprised we didn't see this stock trading down 10%. I mean, I know the company reported earnings, uh, that, that were pretty good for the company. You know, what's interesting is the wa uh, the street doesn't a lot of times it doesn't really care about a little care about the lawsuits. If they end up being, uh, if they ended up implicating, I only care about like certain kinds of lawsuits, right?Like they care about. Like when the DOJ sues you, they care about that. They care about like antitrust lawsuits. They don't, I I'm not saying it's right or wrong. It's just seems like it's the way it is. Um, you know, I can think of like every automaker has had major lawsuits, uh, Toyota with the airbags. I don't really think the street cared about that.I, I think the street doesn't really care about product recalls. They don't really care about like wall suit risk, you know what, here's another one. Why don't you pull up the chart of match, match.com MTC gauge because they have a lawsuit going on, uh, right now, just when to trial or, or, or they're in jury selection, the proceedings have started, um, this is related to the founder.Resewing assuming IAC because he's saying that, um, he, uh, misled them as far as the value of the company when he was buying them. But, um, Yeah, you don't, you don't see stocks react really to tool a lot of times to lawsuits. I'm not really sure why that is. I don't know. Well, yeah, there's some crazy theories being thrown out there about the concert, Spencer.And I'm going to ask you, take it or leave it. The first one, um, being thrown out there is Travis. Scott is like a satanic devil worshiper. What are we talking about right now? That's look it up. That's the theory being thrown out there. I'm asking you to take it or leave it. Uh, I don't need, well, I don't even know who he is, so I like, I leave it.I don't know here. The article from Newsweek, Travis, Scott, satanic festival blood sacrifice, conspiracy theory. Okay. So you're leaving that. You're not buying it. Yeah. I don't even know what that means. So no, uh, it would sell that headline, whatever that means. Okay. There we go. I don't know. I don't even know.All I know is the concert ended in tragedy. It's not the first time. And nor would it be the last time that it happens. I fear cause these kinds of things, uh, um, they happen occasionally for whatever reason. So, um, Hey, I think we're running late for our first guest. That was quite a segue, but we're going to, uh, do that say w w we're going to commit to the segway here.Uh, cause we have, uh, the CEO of a chem tracks backstage right now. It's ticker a C E T X cigar. Goalball let's get him on the show AB well, let's do it. Shugar how are you doing today? I'm good. How are you? Nice to meet you. Nice to meet you as well. Uh, you guys can tell what is on our mind right now by the kinds of companies that we're bringing on with bill, uh, cigar, you are in the VR AR space.We are thinking about that. We are interested in that. Um, so it is not enough for me to merely drop that nugget. Please tell us exactly what it is that you do. Sure. So soundtracks is a diversified technology company. We have several different operating brands, uh, from the IOT sprays to security technology, but also AR and VR, which is a big focus for us going forward.So, uh, we operate a number of different brands. We've been building in VR for the last, uh, three or four years already. So we're quite familiar with this space and we're very excited for sort of the next phase of the computing, uh, paradigm as we get into the metaverse, obviously with the recent news with Facebook.You know, transitioning to the metaverse, um, there's a lot of discussion around this and we think the time is perfect for, uh, for VR now to take off what exactly are you building? Because the metaverse can mean any number of things. It can be anything to do with the metaverse. Right. So, so w so what are, yeah, so, um, so we look at the, metaverse says.A number of different opportunities. It's going to evolve, uh, dramatically over the next 20, 30 years as, as, as it takes shape. Uh, but right now we're very much in the nascent stage of this. And so, you know, our group, our focus is to really, uh, drive growth for our business, uh, in areas where we see early adoption and areas where we see opportunities for, uh, growing our business.So right now, um, we've acquired, um, a training studio that is called virtual driver interactive, where we build simulation technology for, um, right now, just for drivers. But we plan to evolve that as VR is used for training applications, um, we also launched our first gaming studio. So we're building our first, uh, VR gaming experience, um, as part of the metaverse, uh, that'll be launched early next year.Um, and the, the name of that studio is called Bravo strong and reliance. Our first Saifai first person shooter, uh, in, in, in Q1. Uh, so that's really something that we're looking forward to as our first kind of foray of our own, uh, technology and platform in, in the, in the space. We also do make investments in, in VR as well.And so, you know, we kind of have an, all of the above approach of building our own technology, as well as finding and seeding companies that we see big potential in. It seems like everyone is, is, is thinking of training of professional training as like the primary aside from gaming. Uh, the primary use case of the metaverse, you're not, you're like the third, fourth, fourth person to come on our show and mentioned training specifically.So, yeah. And so, uh, I think that's an early, it's sort of, uh, some of the easier, uh, low adoption kind of, uh, uh, opportunities right in front of us. So, um, you know, for instance, I mean, you know, taking large equipment to trade shows, training your customers on, um, complex equipment, it can be challenged. Did you things like that, uh, inexpensive, right.So VR solves that problem. Uh, so, uh, you know, whether it's training sales teams or training your customers, um, that's clearly an opportunity where, um, you know, there's a number of opportunities and, you know, we've even seen this with, uh, you know, sort of in-person virtual training. You can train police forces, chain, you know, fire, firemen, you know, OSHA training.I mean, so there's a number of opportunities across the board when it comes to, to training, uh, you know, with VR, is there another use case outside of the training and obviously the gaming that's really exciting to you? Yeah. So we're heavily looking at, um, a couple of things. Uh, one is entertainment. So, um, I mean you've seen some of the things that Fortnite has done, uh, with, with, uh, their own experience with Ariana Grande day and, uh, uh, and some of the other artists that they've put.So we see a big opportunity as, as that evolves. And we're looking at forming some partnerships or joint ventures to. Uh, some kind of experience in terms of entertainment. Um, and then, uh, additionally, I mean, I think everybody's trying to figure out how to monetize. So you have lots of opt developers that are, um, you know, putting out products in there, but they don't have any easy way to monetize those applications.So we see that as a big opportunity in terms of, uh, you know, ad monetization strategies, you know, whether it's advertising or similar sort of paradigm. So, um, I think there's a number of things that are taking place. And I think as we, uh, we're planning to launch a number of initiatives in, in the first half of next year, as we make more headway in the metaverse space.So the other things that we're doing is we invest in, in VR companies. So we made an investment in a company called masterpiece VR. Um, and so there's going to be more development tools. So masterpiece VR is, is a content creator tool that will. People to rapidly create three-dimensional assets. And as you know, the metaverse comprises of all 3d digital assets.And so, um, you know, we view this as getting on the ground floor of a really great, uh, unique creation tool. Um, that will be, uh, you know, one of the primary tools as developers start to build more and more products in VR. So, um, you know, there, there are a number of different avenues that we're looking to capitalize on in terms of, uh, the next year or two within VR.Um, That concerns me here. Cause like, as I said at the top, we are very interested in the metaverse right now. It is the hot topic of the, of the last month. We, we can think, uh, Facebook slash Mehta for that, but we do this a lot, right. Where we get this idea, we focus on it, we get excited and we realize, oh wait, we're still awhile away from adoption.And then we move on. Um, and when I say we, I mean the public investors, the media, right? Whether it's cannabis, whether it's Evie stocks. Um, and, and that concerns me here now with the, with the metaverse um, I think I saw a comment. I think it was a CEO of 10 cent. I could be wrong that said like, everyone like slow down.Like it's gonna, it's going to be, this is a long-term thing, but it's going to take a while. Or maybe we're maybe we're getting ahead of ourselves. Right now, do you do, do you agree with that sentiment? Okay. I do think this is early days, you know, I mean, when you think about Amazon, you know, it started in 1994.Right. But, you know, I mean, you know, you think about 20 years later, it was really when the true premise of what Amazon or the Bezos vision was really kind of materialized. I think this is sort of a similar kind of paradigm where we're in, uh, in the early stages of a, uh, computing revolution that could largely, you know, it could be larger than the mobile computing revolution and, um, has the potential for, you know, massive value creation.I think it is still very much early days and that we are, um, you know, there are a lot of opportunities, right. Uh, for, for picking, however, You know, it's going to take some time for the technology to evolve for the bandwidth constraints to evolve. And we're going to start to see that over the next two to three years.And I think from that point onwards, it's just going to get better and better with each, each year as the technology improves and makes it easier for the average person to spend more and more time in VR. Right. And so when you look at like computer usage in the early nineties or late eighties versus where it is today, it's a similar paradigm that you're going to see with how many people, how much time the average user spends in VR today versus 10 years from now and 15 years from now and so forth.So, um, but that doesn't mean that, um, there aren't, you know, the Amazons of tomorrow that are right for investing in or, or, or focusing on, right. People don't realize that Amazon. Like a decade to figure, figure it out, at least in terms of inter actually know in terms of the business, in terms of the stock.Right. Uh, so, um, I, I, and I, I guess, you know, you mentioned a couple of those initiatives that, that, that you're focusing on, uh, in the, in the first, I guess, quarter or so of next year. Can you, can you, can you pick one and tell them. Yeah. Sure. So, um, so we see obviously gaming is, is one of the biggest opportunities, um, to really enter the, enter the VR experience.And so, um, we want to build a brand for our sales, build a name for ourselves, and we felt that that was the easiest way to start to get in the door. And I think naturally, uh, you know, we believe that much bigger than gaming is our, is our, um, is our thinking. But, uh, you know, we want to kind of start with that inch into it and then start to evolve kind of what we're doing.Uh, I think in general, the entertainment experience is going to be crucial for, um, what can be done in VR. So we've see that as a launching pad for educational experiences in VR, um, for creating entertainment experiences in VR, you know, reading your favorite book, instead of reading it, you could experience it in VR.Um, you know, so things like that I think are where we want to see this go. And by building our first game, we started. Um, build that infrastructure in house and start to set the tone of what we're trying to do, um, and, and start to, uh, kind of unleash the potential of, of what's possible in VR. So I think this is sort of, um, you know, we are trying to ride the wave of VR and as you know, to your point, this is going to take some time to evolve.And so we kind of want to ride that natural organic wave into the, into the, uh, into the future. Uh, Kenneth, uh, Pivar prior, I'm not sure in our chat says that you need some paintings on your wall, but no, he doesn't. You just need some VR stuff on the wall, some AR stuff on the wall. I think that's the paintings are so 19th century.We don't need that. We, we need some VR on the wall. I'm sure I'm not, I don't know how that works. I'm sure you can probably figure it out. Um, and then, uh, the last thing is Ryan Norris asked if, uh, uh, if you can share what you'll be presenting, uh, at the, uh, AR uh, reality event coming. Um, I think, uh, that information should be available on our social media accounts, if you ping them, uh, you know, that information should be there or on our website.Um, you know, but we'll make sure we put it out on Twitter or something where, you know, when there'll be presenting. Uh, and then I guess my last question for you is like how far away is a company like yours from profitability? Not that that ma makes a difference necessarily now, but is that, is that on your radar?Yeah, I think, listen, uh, I, you know, focusing on profitability is crucial for us. I think, you know, we all also trying to balance that with driving top line growth, you know, so, uh, especially when it comes to these cutting edge industries where, you know, requires a good amount of software development and, and, uh, and, and investment in sales and marketing activities.Um, you know, our first focus right now is to continue to drive partnerships, drive top line growth. Um, I do think that profitability is on the horizon. Um, you know, but really right now, our focus is to get some of our key initiatives within all of our segments, um, uh, going to sort of the next phase of our, of our product roadmap and, and hopefully, you know, all of that will continue to drive top line growth and ultimately, um, a higher return on our equity and, and profitability.Awesome. cigarettes, CTX, and he's joining us here on Benzinga live and we appreciate that. Have a good day, have a good rest your day, sir. Thanks. You too. All right. Uh, AB are we running behind schedule? I don't think we are. I think we're somehow. No, we are on schedule. It looks like we're still waiting for our next, we never run on time.This is good. We're waiting for our next guests, Lana chin from a newborn town to join us. I'm sure she'll be joining any. Um, let's go ahead and get cigars banner off the screen. There we go. Spencer, anything in particular you're watching today? Uh, yeah. Yes, frankly. There is a lot of stuff going on in the pre-market session today between, uh, earnings between, uh, the inflation number, like you mentioned.Uh, I was watching Coinbase. I was watching Coinbase because I wasn't surprised by their, uh, by, by what they said in their earnings report that, you know, and maybe we can bring the chart up there and, uh, just, uh, they saw a massive slowdown, right. Uh, in, in activity. And that led to a dry mess, uh, in top line revenue.Um, you've got two catalysts, you've got a bear catalyst, which was the negative or the not so great earnings report. And then you have your bowl catalyst, which is the fact that crypto is at all time highs, but like you said, that was going to be, my point is it's sort of a. You've got on the one hand is a declining, declining retail activity, which they themselves said.We, on the other hand, in theory, there should be some kind of a correlation with Bitcoin. So here's your, you know, when I go down to the five minute chart, you can see here, the, you know, I guess tale of two tapes, you've got the, uh, big leg down after the earnings. But if you, if you just start right there and the stock's doing pretty well since then, um, like you said, I'm not surprised about the bad earnings report because of course this is going to the previous quarter, so it's not taking into account, uh, necessarily all the trading that's happened over the past month, two months since Bitcoin has had its epic turnaround.Um, and the previous quarter wasn't necessarily a great one for crypto. They talked about how, uh, trading was down, like you mentioned. So I dunno. I mean, I, if you went in there and bought the dip right here, you're looking pretty good. I, I think we'll have to see kind of how if Bitcoin and. Blast through there they're all time highs and continue to rip higher.I know a lot of people are calling for Bitcoin to hit a hundred thousand. By the end of the year. If that happens, you can bet your bottom dollar Coinbase will be trading significantly higher. But I think right now I'm just sticking on the sideline. Um, you know, waiting to see kind of what happens. Brent, Brent Slava must listen to the call and sort of Chris catchy because they're saying, oh, it's all about the NFTs, but I didn't know this until the call.So I'm sorry guys. I guess the hyped out the NFT, uh, bandwagon on their call. Uh, so I guess that's a cannabis that I didn't, that I have not considered yet, but, uh, Hey, I have a corn based account. That's where I have my, my, my crypto through. I feel sometimes like I didn't do enough research before.Deciding to open an account one day and, uh, on Coinbase, but that's the brakes? Um, well I think the NFT, it goes hand in hand. I think if we see the NFT hype continue the way what it's doing right now, then we'll see a theory, um, continue to arise. I mean, I think if we, if we see, uh, you know, some wind taken out of the NFT sales per se, then, uh, we'll, we'll see that in the price of Ethereum and other crypto.So I think it's all hand in hand. The NFT though, is I think being taken more and more seriously among the, from the institutional side. So really, no, this is not, this is a Rico story. That's not a bad thing. That's not a, I'm not saying institutions are going out by. Um, a bunch of NFTs. I'm saying more from the sense that like Coinbase is saying, okay.Yeah, we need to get into this space. Um, so more and more big players we'll see, get into all right. I'm also watching Riverton and Ford ravine. There's nothing to see right now. You've got the news feed up on the screen, right there from Benzinger probate that you can see. So, you know, not a real surprise here to see, uh, the stock, uh, going to open above its IPO price of $78 per share.Uh, if you think back to like a week and a half ago, the original, the estimated range was what like 55 to 60. They priced the last night 78. And you can see here all the headlines we have in the pro, as we wait for Vivian to open here, we have, Sherry's indicated as high as 125. Dollars today. Um, so they're still working through the order book, trying to figure out who gets what and at what price, um, and when they get through that, we will have, and we will open and then I'll be watching Ford on top of that.Um, I don't know where Luke Jacoby is or what he's doing right now, but I really, really hope that he sold some of his Ford costs today. He made a fan task trade, and I pulled the Ford chart. I just, I worry here, and this is a daily, so this is good. Let's keep this up. This is a daily chart of Ford. I don't know what the future holds, but if you're all big in, in Ford after this massive run, I would strongly, if it were me, I would definitely take some of my money if want all my money off the table here in Ford, if it was.I don't know about Uribe. Yeah. I mean, anytime that you have the type of returns that Luke has had on this trade, always a smart idea to trim some of those positions. Um, but it can be fun to let them ride too. We will see real fast. What is Ford's market cap? $80 billion. Okay. What is ravines market cap going to be?Well, the valuation was at 65 billion. What was that at? 78. Was that 78? I think that was, um, that was at 70 bucks a share. And we're now potentially $30 above that. Right? We're talking what, like 40%. I don't know that math is hard. I don't know. But, um, so is weaving going to have a higher evaluation than.What's uh, what's the thought process behind Ford owning 10% of heaviness? Is it just the fact that Vivian's going to be a direct competitor? So if they start taking some affords market share that at least forward has some stake in the game. Yeah. Ford and GM. We're both trying to invest in, in Vivian for, uh, for, I think Ford, uh, thought they had it and then thought they lost it to, uh, to GM and the GM thought they had it, but then Ford got it back.Um, uh, pickup trucks are the number one selling vehicle. It's Ford's number one selling vehicle pivoted to a few years ago. Right, exactly. So that's why I'm curious. It's because like I've revealed truck is directly competing with the Ford lightning electric truck. Yeah. But it's more. Yes, but it's more of a case of like, they all have to compete with Tesla in a way.Right. So not really, I don't think the cyber truck's going to be a thing for another. All right. Here's a good one. Take it or leave it. Buyers sell cyber trucks will be on the road. This time next year? No. No. So what about this time? Two years from now? Sure. You think so two years from now? I don't think so.Okay. Definitely not next year. Um, look I Ford and GM, they, they do, this is what they do. They make investments across the space, right? Why the GM go down then the Nico, the rabbit hole, right? It's the same idea. They have to make an investments in this space. So this is part of that. Um, all right. So young money is saying he's selling a one year out cyber truck, but buying two years.Yes. Brent, this is new. This is our new segment. Take it or leave it. Yeah, we came up with that like two minutes before Showtime. Yeah. Let me, well, let me try to think of some more, some good take it or leave it. Well, while you do that, I'm, I'm still just watching the news feed here on reveal and, uh, I would expect it would open within the next day.I obviously can't say for sure, take it or leave it Rivy and shares will be trading with why are we doing, I don't understand why we're doing this, the take of the, even on everything, take her to leave and take, Hey, take it or leave it on, take it or leave it, chat, chat, let us know what you think. But I go back to my point, Luke, I don't know where you are, but if you are, please sell your Ford a little bit.Thank you. Um, because he made a great trade and I worry about days like today being a topping event for, for, uh, uh, Suffolk Ford. So, um, there's that? Okay. Uh, it is 1237. I do not see our next guest here, which means we're going to just keep on rolling. And, uh, we will have, we will have a, uh, another guest coming up at 1245.Uh, the CEO of a equipped, uh, medical Greg Croft will be on the show, uh, in a few minutes from now. Uh, let's go back to our dock where we planned the show to. And I wanted to talk about, let's see, we hit on Coinbase. We hit on Trivian. Um, I want to talk about Disney actually, because Disney reports earnings tonight.They're in my never sell portfolio, but we have two events coming up. We have earnings tonight and we have their, uh, their Disney plus streaming extravaganza, whatever you want to call it event on Friday where they're going to like, say, Hey, look, look, you know, all the really cool stuff we have coming up on Disney plus.So two potential catalysts for Disney, the chart doesn't look great. Can you pull it out please? The chart does not look great right now. Um, I think it was trading around its 200 day moving average, uh, this morning, maybe, maybe the fifth today. Let's go out to the daily chart. I don't know Spencer it's been trading sideways.It's done nothing for the majority of the. Almost the entire year ranks and nothing for the last, what the high was in March. Right. Um, we go back out high was right here March. Yeah. So we've done nothing here for, for nine months. Sometimes stocks just like to take a little break from, yeah, I know. So I want to know how you feel about this.I want you to, you can, I don't intend to, I'm not selling this thing, but, but what can we think about this in the context of like Netflix and what they said? Cause they cause they're, you know, they pumped the brakes on their earnings report. Uh, Roku, Pomona, the brakes on theirs as well. Um, and I, I don't know.I I'm, I'm worried, like I can wake up on Monday and Disney's. I don't know what, if we did like a straddle on Disney where we said, we think it's going to move at least a 3% neither direction that yes, actually you want to set that up? Because I would definitely, I've never put it on a spread before, so Oscar it up, but I would take that bet who is, um, you know, let's wait, let's wait for Nick to come on.Okay. Nick Shaheen is our options guy, but what let's have Nick walk us through, uh, but he's not going to want it to it. Like I, it's not going to be as much of a Yolo trade once Nick is on your right. Nikki, Nick is not going to yellow his money on him. It's going to be very like defined loss and that's, that's fine.That's boring. Yeah. All right. Oh, uh, from affirms reporting earnings today, uh, I mean, uh, firm's just been an absolute monster ever since the, uh, the Amazon deal. It's coming off a little bit. Well, wait, the earnings are tonight and it's already down 12%. Sounded good side. He'd be running sorority. Yeah.Someone in the chat said, um, affirming there's 10,000 of these a day. I can't keep up. Yeah. And I'm sorry, the earnings were not out after close today. So does someone just know something we don't know? And that's why the stock is trading down. You have to look at it within the context of like, what is trading up and what is trading down today?Oh, so many of these hot stocks are just getting like punished right now. Like how has the pop up start ups T how's that hanging today? Not great. Spencer. It's down about 18 and a half percent. Yeah. I mean, it's up from the open, but the boat that's down this upstart do loans. Okay. That was it. That was a trick question.You're trying to get me. It was trying to get me. I know I've started. Does they do wounds? There are FinTech lenders smash. The like, if you got that right. Um, any, any other stocks that were watching some crazy movement on today? We I've been watching roadblocks all day. So roadblocks from mortgage monster quarter.Great earnings was up about 20, no 30% yesterday. And is now trading lower, uh, by about 8%. So this might just be a little sell off after that massive rip up or, uh, I don't know. I mean, a lot of times when a company reports great earnings and it goes up like 10%, my thought process is all this can't keep going up.And what does it do? It keeps going up. How many times have I said that to myself this year too many, but, so I actually bought some roadblocks yesterday while it was up about 30% and now it's down 10%, so who knows? Nice. Very nice. Uh, okay. We'll have our next guest on Greg Crawford in a couple of minutes.Let's catch up on the chat. Um, happy saying reveal and shares will be indicating at 105 that's unconfirmed, but, well, that's just, that's just the block. That's just a block of shares. We have to get to the whole thing first. So, um, yeah, but you know what let's do, let's do an informal survey slash poll on the chat and whoever gets closest, we'll get some swag.Okay. Drop your, and drop your price in the chat where we'll reveal and open know that the IPO price was 78. The most recent indication was 1 0 5. The highest indication was 1 25. Um, drop your number in the chat. What price does ravine open for trading at when, if it even opens today? That of course it opened that wasn't to.Ah, we got some numbers, 1 2197 96, 1 25, 1 to 32 voodoo. Wow. That's Polish 81 proton 81. I think you're on the low end of that one. Proton. Uh, we got, when we got 90 in there, we got 94, 1 29 50. I love the, the, the specificity of that down to the penny. 1 25 51 to three, one to 5 93, Shelly 64 K. Get out of here, Shelly, 64, come on.Be serious. Okay. So I seem to have a consensus of a, someone on the 1 0 5 to one 20 range. We're waiting for this. And when it, when it comes out, we will be, uh, we will be there for it when it happens. Of course, in Cal asking this. Uh, the million dollar question is where does it close? If I knew that answer, I'd be a very rich man.I guarantee you, man. I almost, I want to bet right now. You want to bet on, but I don't know. I want to bet it closes. It closes down from the open. So, uh, you're coming from the open. Huh? That's a good, that's a good point. Cause you can't trade it. You can't trade options. Yeah, it will close up from the IPO and down from the open is my, that's not a very hot take though.That's I think that's that's that's that's a common thing we see. There are sites you can bet on certain events on. I don't know. That's a good question, Spencer. Okay. Uh, while we digest that let's bring on our next guests. Um, this is an interesting one, uh, this, this company, uh, in many respects and you can see it in, in the chart of their stock, uh, is seen as a COVID play.Uh, and now that we are. Uh, hopefully maybe trying to come out of that, uh, companies like our next, uh, our next one, our, our, our, you know, figuring out where they stand in the future here in a real post code the world. So Greg Crawford is the CEO of Quip to medical. That's getting them up on the screen if we can.Mr. Crawford, how are we doing today? Doing great. How about yourself? Thanks was my, was my introduction, a fair assessment. I have to tell you as far as being a COVID play, I think you're off on that COVID is held this company down and that for over a year and a half from executing on our organic growth, although we've grown about 10% over the past couple of years, each year, we're on pace this year for 11% or so.Uh, but, uh, well, I had, I had assumed though, cause you, you make ventilators. Yeah. Yeah. But all of our services are, uh, home-based services, um, here, uh, patients inside their homes. And we have not been able to expand our Salesforce and, and our current Salesforce has not been able to quite go as deep as they'd like to in some of the different referral sources because of the visitation restrictions and things like that.So we think we're going to do much better once we get outside of COVID. So of all the different products. And I mentioned the home ventilation, but you guys also, you, you, you make a sleep apnea, um, uh, treatments, uh, and, uh, and of all your different products and services, what, what is, what is the highest growth area right now?Yeah, so the highest growth area for us really, it's just across our entire respiratory category. So this year we're up about the 40% and that just over 40%, about 10% of that is organic. Uh, so we continue to see strong demand for all of our products as just the overall. For home-based care and services.Uh, it has been going on for quite some time. And I think COVID is really just kind of brought it more to the limelight rationalization is that these patients can be taken care of in the home setting rather than a hospital setting. So, yeah, go ahead. Oh, I was just gonna say, so Greg, you you've spoke before about the company's acquisition strategy.Um, and I'm just curious if you, if you can outline that again for our audience here today. Yeah, sure. So we have a three tiered acquisition strategy. Um, right now we would consider ourselves kind of a regional player. We're currently in 15 states, uh, uh, this year to date we've added five new states. Uh, so we continue to look for opportunities in that to expand into new states, uh, obtain new insurance contracts within those states.Uh, and that's kind of the first tier in that of our acquisition strategy is, is really looking for so. Uh, $5 million type companies, but they, uh, they've got an infrastructure and they hold a lot of insurance contracts that allows us to kind of go in and capitalize on that particular market that they're in.And then also add continuum markets. I'm sorry, I didn't mean to interrupt. Keep going. Yeah, no. The second tier of our strategy is to look for heavily weighted respiratory companies. Uh, typically those companies we're seeing in the five to $20 million top line revenue range, uh, and then the third tier, and that is to look for much larger, more material size acquisition from a revenue standpoint and an EBITDA EBITDA standpoint.And right now with our a robust pipeline, we've got all three of those, uh, to date and that we've, uh, since about, uh, July, we've closed six acquisitions for a total of about $16 million in top line revenue growth. Wow. And how are you funding this? Um, mostly all cash with our. Current cash on hand. So, uh, occasionally we will, we will issue some shares if we want to align some management in that with our culture to keep them on.So Greg, I understand there was a, a recent acquisition. Do you want to go ahead and speak a little bit about that? Yeah, sure. So we just expanded in the state of Illinois in that, uh, via the way of an acquisition, uh, was a really, uh, Illinois, a very important state for us. It's one of the top, uh, states there with, uh, patients with, uh, high acuity of lung disease and COPD.And that's what we're really looking to heavily expand in that state, but it also kind of aligned a Metro market for us in, in that, between us St. Louis and Chicago, uh, where we currently have operations. Uh, so, uh, we were able to add about 3,700 patients and about, uh, two and a half million dollars in top line revenue and also connect to geographical areas along with some important insurance contracts to operate in that.Greg, you mentioned COVID being a headwind in that it, it did sort of hinder your Salesforce a little bit, but I'm curious aside from that, what have you observed in the last year and a half in terms of, um, patient behavior? Uh, for context, my, uh, fiance doesn't anymore, but she used to work in a senior living community and, uh, she just recently left, but having worked in, you know, there for, for a, for seven or eight years, uh, and the changes that she saw in the last year and a half, uh, we're we're startling just in terms of.Just their census was got so low. And part of that was due of course, to, to, uh, to people passing away, but also people not moving in. Right. So, and, and choosing to stay at home more. Uh, and I'm, I'm just curious what, what you've observed in terms of patient behavior in the last year. Yes, absolutely. In that, I mean, that kind of, uh, dovetails off of our story here in that, whereas we're taking care of the patients and the home-based setting in that, and they require our equipment and our services to go along with those particular products.So, so that's where we've really been, uh, stepping in and making a difference in the marketplace. There we've seen trends in our referrals, in that we've primarily been hospital-based in long-term care based kind of referrals in that, which is what we, that's where the majority of our business comes from.But we've seen a lot of that, uh, go direct to the physician. And that's a, rather than that, physician may be sending them to the hospital or long-term care. We feel that, uh, they're, they're ordering these products directly from their offices. Uh, and we think that we're also getting these patients earlier in the onset of their disease state, uh, which bodes very well for us because then we're able to keep them on service.Yeah, this, this to me seems like a demographics play more than anything else, right? It's it's, it's, it's a family thing. It's just a bet on getting older and needing, needing more medical attention. Yeah. Yeah, definitely. There's 10,000 people turning 65 or older every day. And that's, that's really, that's our core market.Uh, the market itself has grown about five or 6% a year. So we've kind of been, uh, doubling that the past few years. So you mentioned expanding to different states. You mentioned Illinois, uh, is the eventual plan here to be in every state because right now you're in, I believe what, like a dozen we're in 15.Yes, absolutely. We're looking to build out a national presence in that as we continue to expand in that, uh, both, uh, organically and inorganically through acquisition. So Greg, um, as the industry of kind of home health care grows, are there areas that you think investors should be looking out for ways to kind of invest in the home care industry as a whole?Like, is it in telehealth? Is it in companies like yours that provide, uh, equipment for people to have at-home care? Yeah. I mean, it could be all of the above. I think anything that's home-based care, whether it be home health or it'd be durable medical equipment or a, some type of tele-health or something, uh, you know, would definitely be a good investments if that's what you're looking to do with your money.And what do you think the timeline is on that? Do you think? Uh, like the whole look of healthcare looks different than it does today in, in 10, 20 years down the road? Yeah, I think, uh, the push for home health care, and that is only going to continue in that. Uh, and I think, uh, COVID has really kind of brought that to the limelight that, uh, now physicians.Insurance companies can see that these patients can be taken care of and in the home setting, rather than going to a long-term care type setting or a hospital or something for some of their, uh, elements that they need treated, especially with our remote monitoring patient, uh, features that we have on our ventilation and our sleep products and things like that.Greg, you mentioned in your investor deck, the, the strong regulatory or the favorable regulatory environment right now, uh, what, what exactly makes the regulatory environment so favorable for equipped? Yeah, so for us, so there's been a program that was implemented in 2010 called the DMV competitive bidding program.Uh, that's where the industry really had undertaken some drastic cuts from 10, 2010 to 2016. You've seen a lot of consolidation in the industry at that time. Um, but really since 2010, uh, or since 2016, I'm sorry, the industry has not seen any, uh, significant reimbursement. And the program, uh, the DME competitive bid program was set to take effect January 1st, 2021.And it was actually, uh, Medicare had removed, uh, 13 product categories, which is essentially everything that Quip provided to Medicare beneficiaries. Um, for this round, that was to begin January one. And the reason they removed it is quote their, their quote. They did not achieve the expected savings. Uh, so.When the rates actually came out in early January of this year and that they were actually about 30 to 40% higher in some major metropolitan areas, uh, for services that we provide. So, you know, we can definitely see why they remove those because they sure didn't want to pay us additional. So we think with where the rates sit right now, uh, you know, we're just got a clear outlook in that for what our fee for service looks like in that, uh, for the foreseeable future.Also we've recently here in 21, we've also received, uh, some increases, um, on oxygen rates that had begun, uh, April 1st, 2021 also, uh, for home oxygen, there has been some changes in that to the coverage determination, and also for the types of patients that they cover in that. Now patients with acute diagnosis is beginning in 2022 will become.Uh, for home oxygen services and also they've removed some of the burdensome paperwork that's required. Uh, in curious as the medical device side of your business, I'm wondering if you have seen or felt any sort of supply chain scrubbiness yes, absolutely. That's the official term, by the way, if we had to pick something wacky there in that, uh, you know, going on a headwind in the industry, it would definitely be supply chain.Uh, you know, so we've definitely had that. We've had it throughout the entire pandemic. We continue, uh, just access to a certain products and services at a given time. Uh, but we've done a great job of managing through that. Being able to forecast what our needs are and that's really, that's still kind of driving the organic growth is our ability to actually get products.So I think we're doing better than, uh, probably a lot of other providers out there, especially a lot of the quote, mom and pop providers out there. There's over 6,000. So with our buying abilities, uh, in our forecasting abilities and that we've been able to kind of preplan a little bit better. Yeah. I find it so fascinating because it seems like the access to this at-home medical care, it's almost like we're going back in time to when it was commonplace for doctors to make home visits, of course, with new technology.But, um, I just think this industry as a whole, as far as being able to get medical care at your home, uh, is fascinating. We'll continue to grow. Yes, no doubt about it. I think we're seeing everything home bare, uh, home-based care or anything kind of go home base from delivery service of food and, and Dayton all the way back to get your milk delivered.I guess you could say. You can get groceries delivered now. That's true. I hadn't thought I hadn't thought about it like that, but, uh, that's a good point. Greg Crawford is the CEO of Quip medical us here on Benzinger live. Greg, appreciate the time. Have a good one. Thank you. We appreciate it. Have a great day.All right. Uh, let's get that banner off the screen and we're going to have our next guest on in a couple of minutes. Jessica Kaylor will be joining us. So, uh, we'll be talking some trays and some charts with Jesse at one O clock. Uh, in the meantime, Riviera has not yet opened. I actually, haven't seen a new indication in a few minutes.Talk about Uber puts in the chat. Yeah, a lawsuit. Um, I guess from the DOJ regarding the America, the ADA, the American with disabilities act. Um, again, we talked about this off the top of the show, right? I just don't for whatever reason, I just don't think. The street really cares about this kind of a headline?Well, I think what's interesting. And what I always like to do is if I'm looking at a company like Uber, I want to see its relative strength or weakness compared to peers. So obviously with Uber it's biggest, uh, peer would be Lyft. Uh, but you have others as well. Like door dash is up a bunch today, I think on strong earnings.But, um, the, the fact to me, when, if you just look at it, I mean, Lyft is down too, but Lyft is down about one, about 1.3%. Well, Uber is down. Let's see about, about 3%. So to me, that's showing saying that look, investors are, uh, you know, there's more sell pressure on Uber than Lyft today. And I don't know. I mean, I, I can get behind some Uber puts, I already don't like Uber.As a, as a, as a stock. Really? Yeah. I mean, the company just has profitability issues. They have a legal problems as easy Mike is pointing out. And like you said, let's zoom out on a weekly. No, let's go to a monthly on Uber, Spencer. You were talking about this the other day that you, you just think the, um, I guess business model of, you know, the, the food delivery, the Uber, I think it's wrong.I think that, I think it's terrible for small businesses. Yeah. And I mean, I don't know. I think, I dunno. I, I, I'm looking at Uber puts, I'm not saying this is this stock's going to trade lower in, in the next week. I don't know. I don't know. Make a call. Um, give us a hot take, make a stand standing for something.I am buying I'm tailing. Easy mic, easy mic. That's good enough for me. Okay. All right. And the fact that I already don't like the business model. Uber, uh, for whatever it's worth, um, is, is, is trading above. Speaking of IPO is trading above its IPO price, um, and above its opening price of $38. So it took a long time to get there, took over.It took over a year to get there year and a half, but, uh, finally falling in the black, if you bought Uber on day one, um, okay. Are going to keep our eyes on reveal fun, just to see in this pulpit chart here, just to see when it opens. I don't think it, it has, uh, our IVN. It has not, but when it does open, we will know, and we will talk about it.But in the meantime, let's talk about, uh, some other charts with Jessica Kaylor from elite trading. Jones's every Wednesday on this show, we'll bring him on now, Jesse. What's up, man? How are we doing? Oh, it's doing great. How you guys doing? Uh, we're hanging in there, man. Hanging in there. It's Wednesday. It's daylight savings.It gets dark at like two o'clock now. And, uh, it is what it is. So, uh, what stocks do you watch them today? There's a lot going on out there. Um, I was watching the bank stocks, uh, looking at some hotel resorts, you know, rrr. Um, I've been looking at the Neo node. The one that I brought up actually with you guys, uh, sometime early last year when they were around six, we, we had that target of nine currently.I'm almost breaking that $10 mark. So I was going to go show you, share that one off today. Um, but let me share real quick. Did we, do we just get, do we open upour, it was $6 and 75 cents. $106. I have to refresh my, my chart now $106 and 75 cents for revealing bada Bing, bada, boom. I'm not going to go back into the chat and see who came close. I'm sure one of you came close here. It's 1 0 8. It's rolling. Let's see, I'll go. Since Spencer refuses to. Thank you. Thank you.I appreciate that. Yeah. Uh, we had someone guests one 10. What, what was it open at 1 0 8 grant Gibson with a 1 0 9 oh oh Dunkin. Bracey no. Oh, wait a minute. We didn't say what we're doing. Price is right. Rules are not. What is price is right rules. You can't go over and go closest without going over. Dunkin Gothic hosts without going over.But technically grant came closest. Ooh, wait, why did grant come open that? What 1 0 8 74. Sorry, James sands. He has, he always says hi every day. We had a couple of guesses for 1 0 9 AP grant Gibson. Um, yeah. So good guesses in the chat, everyone.200 and then back down to, no, I, you, you can talk me into one 50 as in the next, like 10 minutes and then, and the end of the day at like 90, but, uh, I think 200, 200 tad high. I remember, uh, when Coinbase opened, it opened at what, like two or 180 or something and went all the way up to like four 50 and came back down.Oh, ribbons already. Let's see. Well, there's your first road. Nice little red candle. There always wait, it was one of a six happy saying 1 0 6 75. Wait, did I misread? I may have misread it. Oh, it is 1 0 6. Oh my God, Spencer. I screwed up. I messed up. I screwed up. I thought it was 1 0 8. This was one of those off by only $2 back.I, I take back what I said about who was closest. So we're looking for 1 0 6. I'm sorry. I'm sorry. My mistake. I'm sorry. 1 0 6 75 IPO price. It's 78. Congrats to all those people, because they're now making money on their long-term investment. Right. Um, anyway, so we got sidetracked with Vivian. Can we go back to what was on your list?Yeah. And just talk in, um, touch us. I just shared your charts. W w this is Teledyne. Yeah. TDY. They're the biggest competitor to Nia node. And neon was the one that I was talking about earlier, which is touchless. They do like touch of technology for like elevators, um, things of that nature for the future.So. Um, I will have a future. Yeah. Where, you know, a lot of people go in a lot of button touching. You don't want to get in and touch the elevator button. So if you could go up and just like, put just barely even put your hand over the button, then it'll actually put it up, pull it up for you in there. They got a big contract for that.And then they also have it to where they can attach to windows 10 capable computers. And it makes their screen touch screens, uh, touchless. But, well, this reminds me of a game that we used to play when I was a kid, uh, my cousins and I, whenever we w the family would all go to a hotel or whatever the game was run until the elevator hit everyone at the same time and see where you see where it takes here.And you wonder, how do you want to know how that game ended? This is the true story. You all know how that game ended and did it with us stuck in between the floors a little bit. Yes. I swear. I have a cousin who to this day will not get into an elevator with. That was like 20, it was 25 years ago that this happened a little bit less than that 20 years ago.Uh, and he will not get into an elevator with me cause we got stuck and true story anyway. So nobody get on the elevator with a joking. Hey and real quick, other side note, uh, that was actually not my first time being stuck inside an elevator. I've gotten stuck twice. Um, the first time was actually I, uh, the doors closed on me.Um, when I was like six years old, it was a traumatic experience. The bottom line is, do not get into an elevator with me. Okay. If the bottom line here. Um, anyway, let's go back on the charts. Yeah. So we were on, um, with you guys back where this line is here and near at. Um, . Of 2020 and we were watching the same play and we were talking about it as touchless technology.I think I just felt like it was, this is an old company they've been around since 1976. So it's not like a new company and they've, I think this is just finally the, the environment that they needed to. Maybe break away. And when you start looking up, okay, who's are their competitors and you look at TD why a $400 stock, you start thinking, okay, maybe there's, there's a space here that hasn't been touched by a lot of people.And these there they've been in it for a long time. So it's just kind of a long-term idea. Play for me. Maybe they get into this whole metaverse if there's a lot of need for touchless technology in the future. As in video gaming, uh, health wise restaurants going to touchless, um, ordering, servicing stuff, like order style.Um, I think that this is, I think they have a lot of room to grow, so just one that I'll be watching, but today in particular did take a little, um, position in GLD. Um, that was. What are you a boomer? Nah, just, I, I heard triple D talking about it and I was like, you know what? I'm already, I'm already thinking banks, everyone in the chats going and talking gold.And I think that, you know, it, wasn't working for a hedge play for a lot of people, but I just wanted to get maybe 80 cents to a dollar, just a little bit, just to have some green today out of the red morning, I woke up to and I made, you know, made that, made that dollar I needed out of them. And I'm not a huge move in a stock.That's $173, but at the same time, it, if it's green, it's green, right? Well, for people like me, that's looking at roadblocks and trying to figure out a way to play roadblocks when it was up 30% yesterday. Now down 10% today, or 8% today. Uh, w what are some options on how we can, you know, play this? Um, if you're synthetically longer, you can sell, puts that are deeply, um, out of the money, maybe, and at a, at a position that, you know, maybe a strike that you would feel comfortable buying them.And then you collect that premium every week or month until it gets down to that price. And until you're willing to pay for it, and you use that money that you make off the premiums to pay for more of the shares. Okay. What, so, so what if I sold puts at like $80 and then I bought a put at, I dunno, 95 or something.So if I thought it was going to continue to go down for a little bit, but not all the way to my lower strike price, then you're going to make that money off that 95 all the way as it goes down. And then you're going to also be able to collect that premium as long as it remains above that $80. You just want it to just end up between 80 and, um, what'd you say?95? Yeah, something like that. I mean, do you think something like that? Is it. Uh, yes. If you, if you're, if that's the opinion that you're taking on it, you know, if you think that it's going to fall, um, below that range, now you will lose that 95. If it stays above that, you know, you're going to lose out on that, whatever you pay for the premium on the 95, that's a potential loss there, but, um, it's going to make the, the play possibly a little cheaper for you.Um, it's a good way to do a spread, you know, on, on a stock that you're comfortable with, that you want to buy. Anyway, I would, I would strongly recommend for anyone that's trying, in my opinion, to buy a stock that they want to get in what they don't think that it's at the price they want to buy it. They just sell the puts at the price that they want to pay for it.And then if you get at you get, now, it can be dangerous, especially with Snapchat. Why didn't I do that? Well, so, so, but if I wanted to just sell. And I wasn't doing a spread. You need to have like a certain amount of money in your portfolio to be able to do so, correct? Correct. Yes. But buying us or doing a spread versus just selling the put alone makes it a little bit more affordable.Yes. It alleviates some of that, um, equity that you have to have. So it's, it's all about positions. You know, how, you know, when you're talking a hundred dollars stock, you'd expect someone to have that decent amount of, you know, buying power available. If they're looking to buy a hundred shares of a hundred dollars stock, you know, that's a, that's a big, that's a big one, you know, I think, um, that we're talking, but it's good for people when you're talking, just trying to make premium, even just to, just to do it, like uses, like you just suggested you could do that same way by the 95, sell the eighties and collect that premium regardless of what you want to do position wise in the.Got it. Uh, rich Williams saying good afternoon, everyone from Florida. Good afternoon, rich. How are you doing? Let us know in the chat, what stocks you were watching. We'll go ahead and take a look at them with Jesse. Uh, Jesse, any other trades that you're looking at that are setting up for you? Um, I did want us to just see where it's at one 16.Oh, nice. I'm also watching China stocks here. Cause I guess easy Mike noted it and I don't even know who care, but every grand officially defaulted. Do we care about that? I'm watching China. That sounds bearish for China stocks, right? Nah, that sounds bullish. Cause we brought the dip. So, um, but there has to be a dip to be bought.The dip already happened now we're buying it. Oh, okay. Beautiful. Oh, I'm watching something that I wasn't even mine on my radar until yesterday. That's highs on motors, a ticker, H Y, Z N having a breakout today. I've got some open calls on the stock. We had them on them. We had them on the show. Highs on uh you're you're going to helium.No, no, no. You sure. Yes. I'm sure they, we had them on one of, I don't remember which show take it or leave it. We've
Ash Francis, man of many hats, comes on the Dash Podcast to talk about all the amazing things he's involved in. We extensively go over CTX, the payment processor that Ash co-founded, and how it processes DashDirect payments and much much more, as well as its future for full launch. We also went into the upcoming THORChain integration and everything it provides, and the Dash Investment Foundation and how it has proven to be one of Dash's most successful projects. We finally go over the Dash Incubator and all the exciting apps and integrations they've pioneered. Donate - Sponsors Thank you so much for listening! Please leave a tip if you enjoy the content, either here or via any of the cryptocurrency addresses in my CoinTree link. You can also send a message with a CoinTree donation. I'd love to hear from you! Thanks to my recurring donors both anonymous and otherwise! - https://cointr.ee/thedesertlynx Support us by checking out our sponsors! Want to live on crypto? Create a Bitrefill account with the coupon code “DCN” and pay mobile bills or buy gift cards from more than 1650 businesses in 170 countries quickly and privately, and earn rewards. - https://www.bitrefill.com/buy/?code=DCN Buy anything you want in the world, even rare items, with crypto by using ShopInBit's concierge service. - https://shopinbit.com/en/conciergeservice-ordering-service?sPartner=joel If you're tired of YouTube and other platforms censoring and demonetizing creators, what are you waiting for? Join Odysee! - https://odysee.com/$/invite/@DigitalCashNetwork:c Protect your privacy online, sign up to NordVPN with the promo code DCN and get 68% off, plus an additional month free! - https://nordvpn.org/dcn If don't want search engines like Google controlling your search results and selling your information, join Presearch and get paid to search! - https://presearch.org/signup?rid=865012 Music from https://www.zapsplat.com
Welcome to PICU Doc On Call, A Podcast Dedicated to Current and Aspiring Intensivists. I'm Pradip Kamatand I'm Rahul Damania. We are coming to you from Children's Healthcare of Atlanta - Emory University School of Medicine. Welcome to our Episode of a 19 month old female with bloody stool, petechiae and no urine output Here's the case presented by Rahul: A 19 month old previously healthy female was brought to the pediatric emergency department for blood in her stool. Patient was at daycare the previous day where she developed a low grade fever, congestion and URI symptoms along with non-bloody-non-bilious vomiting and diarrhea. Patient had a rapid COVID test which was negative and was sent home with instructions for oral hydration. That evening, patient began having vomiting/diarrhea which worsened. She was unable to retain anything by mouth and her parents also noted blood in her stool. Due to this, she was rushed to the Emergency Department. In the ED here, she was hypertensive for age BP of 124/103 mm Hg, febrile, and ill. Specks of blood were noted on the diarrheal stool in the diaper. On her physical exam she was noted to be pale with petechiae on neck and chest. Her abdomen was soft, ND, with some hyperactive bowel sounds, and no hepatosplenomegaly. The rest of her physical examination was normal. In the ED, initial labs were significant for WBC 19, Hgb 8.8, and Platelets 34. CMP was significant for BUN of 74mg/dL and Cr of 3.5mg/dL, Na 131 mmol/L, and K of 5.5mmol/L, Ca 8.3mg/dL (corrected for albumin of 2.2g/dL), Phosphorous 8.5 AST 413, and ALT of 227, LDH > 4000. BNP was 142 and troponin negative. She was given 1 dose of CTX 50mg/kg and a 20cc/kg NS bolus. Stool PCR was sent. She was given labetalol for her hypertension, started on maintenance IV fluids and transferred to the PICU for further management. Rahul to summarize key elements from this case, this patient has: We have a 19-month old child with Diarrhea and emesis X 2 days No urine output for over 24 hours Bloody stool Petechiae on the neck and chest Anemia and thrombocytopenia All of which bring up a concern for hemolytic uremic syndrome the topic of our discussion today Let's transition into some history and physical exam components of this case. What are the key historical features in this child who presents with above? Bloody stool which alludes to an invasive diarrhea No urine output and an ill appearing state which points to a systemic inflammatory condition and end organ dysfunction. Are there some red-flag symptoms or physical exam components which you could highlight? Presence of petechiae which are physical exam features of thrombocytopenia Her pallor which is a physical exam sign of anemia Hypertension which is related to her renal dysfunction To continue with our case, the patient's labs were consistent with: Anemia Thrombocytopenia Elevated BUN and creatinine Elevated serum LDH The patient did not have hyperkalemia, or acidosis on initial presentation OK to summarize, we have a 19 month old girl with: Anemia, thrombocytopenia, and renal failure. This brings up the concern for Hemolytic uremic syndrome → Rahul Let's start with a short multiple choice question: A 2-year old boy is admitted to the PICU with acute respiratory failure secondary to pneumococcal pneumonia. On day # 3 of admission, the nurse reports the patient appears pale and has petechiae on his chest. The patient also has not had urine output for > 12 hours and appears to be fluid overloaded. Of the following the lab findings would be most consistent with the above clinical findings in the patient? A) Elevation of serum haptoglobin B) Low serum lactate dehydrogenase (LDH) C) Negative Direct Coombs test D) Peripheral smear showing schistocytes The correct answer is D-Peripheral smear showing schistocytes. Patient in the above case most likely has streptococcus pneumoniae associated hemolytic uremic syndrome commonly called as...
ReNeuron Group's Olav Hellebo joins Proactive to talk about their exosome technology which has shown it can deliver therapeutic proteins to a hard to access region of the human brain. Exosomes are powerful mediators that carry all the signalling and the machinery necessary to change the behaviour of a cell. As Hellobo explains, the line created by ReNeuron comes from its CTX technology and has been developed to carry the therapeutic proteins as well as delivering it to an exact destination - an area of the brain called the corpus striatum.
New to RheumNow? Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. In this episode, Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com Metanalysis of JAK inhibition (tofacitinib & ruxolitinib) in alopecia areata - 12 studies, 346 Pts, Rx success (using SALT50 resp) was 66%, not influenced by age, sex, subtype. Alopecia recurrence seen w/in 3 mos of JAK D/C (in74%) https://t.co/CBSy4Kci80 Population study shows risk of H. Zoster in adults to be high among bDMARD and CTX, also increased w/ AZA and HCQ but not MTX SSZ or LEF users. Data from 254065, 1,826311 Pt-Yrs F/U, 6295 new DMARD users, 17024 incident HZ https://t.co/1TeOAWN9LB MMWR reports that during the COVID Delta variant era, Vaccination against COVID-19: - Reduces risk of COVID-19 infection 5X - Reduces risk of COVID-19 Hospitalization ⋗10X - Reduces risk of COVID-19 DEATH 10X https://t.co/rMRY84xX5F Study of 265 students w/ a positive COVID-19 test looked at 378 close contacts. Infx rates w both persons masked -7.7%, but when unmasked-32.4% (aORs = 4.9) https://t.co/fYdH33JbWR Effect of Diet on COVID Outcomes Probenecid, an OAT3 inhibitor, has inhibitory effects on RNA viruses (influenza, RSV) & decreases ACE2 expression. May have utility in COVID-19 as it was shown to inhibit SARS-CoV-2 replication in animal modelshttps://t.co/MClSjpqpSa Mease and colleagues have catalogued the current practices assessed in the CORRONA registry, noting that increased DMARD switching and decreased time on a given therapy by US physicians. https://t.co/cIWZw6KsuI A retrospective study of systemic sclerosis patients shows that acute hospitalization and mortality were not uncommon and were often linked to SSc-related lung disease. #RheumNow https://t.co/s5wSlndTrt Cases and Questions (AKA Back Talk) “What treatment do you use after 2 years of teraparitide in a woman with a hx of OP, spiral fracture while on a bisphosphonate”? Forteo PI. “Do you have any inside info on the vaccines for COVID-19 during pregnancy?” OCOG Statement “Status of the Tocilizumab Shortage”? Genentech Statement “How would you treat polyarthritis in a renal transplant patient?” CONNECT WITH RheumNow ✩ Website - https://rheumnow.com/ ✩ Subscribe @ RheumNow: https://rheumnow.com/user/register ✩ LinkedIn - https://www.linkedin.com/in/john-cush... ✩ RheumNow LinkedIn: https://www.linkedin.com/company/rheu... ✩ Twitter - https://twitter.com/RheumNow Listen | PODCAST Apple Podcasts: https://podcasts.apple.com/us/podcast... Spotify: https://open.spotify.com/show/4Mjzj5j... Stitcher: https://www.stitcher.com/show/the-rhe... TuneIn: https://tunein.com/podcasts/Health--W... Podbean: https://rheumnow.podbean.com/ Got a Rheumatology question or case for Dr. Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. BackTalk: https://rheumnow.com/submit-podcast-question-or-comment
New to RheumNow? Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. In this episode, Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com Metanalysis of JAK inhibition (tofacitinib & ruxolitinib) in alopecia areata - 12 studies, 346 Pts, Rx success (using SALT50 resp) was 66%, not influenced by age, sex, subtype. Alopecia recurrence seen w/in 3 mos of JAK D/C (in74%) https://t.co/CBSy4Kci80 Population study shows risk of H. Zoster in adults to be high among bDMARD and CTX, also increased w/ AZA and HCQ but not MTX SSZ or LEF users. Data from 254065, 1,826311 Pt-Yrs F/U, 6295 new DMARD users, 17024 incident HZ https://t.co/1TeOAWN9LB MMWR reports that during the COVID Delta variant era, Vaccination against COVID-19: - Reduces risk of COVID-19 infection 5X - Reduces risk of COVID-19 Hospitalization ⋗10X - Reduces risk of COVID-19 DEATH 10X https://t.co/rMRY84xX5F Study of 265 students w/ a positive COVID-19 test looked at 378 close contacts. Infx rates w both persons masked -7.7%, but when unmasked-32.4% (aORs = 4.9) https://t.co/fYdH33JbWR Effect of Diet on COVID Outcomes Probenecid, an OAT3 inhibitor, has inhibitory effects on RNA viruses (influenza, RSV) & decreases ACE2 expression. May have utility in COVID-19 as it was shown to inhibit SARS-CoV-2 replication in animal modelshttps://t.co/MClSjpqpSa Mease and colleagues have catalogued the current practices assessed in the CORRONA registry, noting that increased DMARD switching and decreased time on a given therapy by US physicians. https://t.co/cIWZw6KsuI A retrospective study of systemic sclerosis patients shows that acute hospitalization and mortality were not uncommon and were often linked to SSc-related lung disease. #RheumNow https://t.co/s5wSlndTrt Cases and Questions (AKA Back Talk) “What treatment do you use after 2 years of teraparitide in a woman with a hx of OP, spiral fracture while on a bisphosphonate”? Forteo PI. “Do you have any inside info on the vaccines for COVID-19 during pregnancy?” OCOG Statement “Status of the Tocilizumab Shortage”? Genentech Statement “How would you treat polyarthritis in a renal transplant patient?” CONNECT WITH RheumNow ✩ Website - https://rheumnow.com/ ✩ Subscribe @ RheumNow: https://rheumnow.com/user/register ✩ LinkedIn - https://www.linkedin.com/in/john-cush... ✩ RheumNow LinkedIn: https://www.linkedin.com/company/rheu... ✩ Twitter - https://twitter.com/RheumNow Listen | PODCAST Apple Podcasts: https://podcasts.apple.com/us/podcast... Spotify: https://open.spotify.com/show/4Mjzj5j... Stitcher: https://www.stitcher.com/show/the-rhe... TuneIn: https://tunein.com/podcasts/Health--W... Podbean: https://rheumnow.podbean.com/ Got a Rheumatology question or case for Dr. Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. BackTalk:
New to RheumNow? Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. In this episode, Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com Metanalysis of JAK inhibition (tofacitinib & ruxolitinib) in alopecia areata - 12 studies, 346 Pts, Rx success (using SALT50 resp) was 66%, not influenced by age, sex, subtype. Alopecia recurrence seen w/in 3 mos of JAK D/C (in74%) https://t.co/CBSy4Kci80 Population study shows risk of H. Zoster in adults to be high among bDMARD and CTX, also increased w/ AZA and HCQ but not MTX SSZ or LEF users. Data from 254065, 1,826311 Pt-Yrs F/U, 6295 new DMARD users, 17024 incident HZ https://t.co/1TeOAWN9LB MMWR reports that during the COVID Delta variant era, Vaccination against COVID-19: - Reduces risk of COVID-19 infection 5X - Reduces risk of COVID-19 Hospitalization ⋗10X - Reduces risk of COVID-19 DEATH 10X https://t.co/rMRY84xX5F Study of 265 students w/ a positive COVID-19 test looked at 378 close contacts. Infx rates w both persons masked -7.7%, but when unmasked-32.4% (aORs = 4.9) https://t.co/fYdH33JbWR Effect of Diet on COVID Outcomes Probenecid, an OAT3 inhibitor, has inhibitory effects on RNA viruses (influenza, RSV) & decreases ACE2 expression. May have utility in COVID-19 as it was shown to inhibit SARS-CoV-2 replication in animal modelshttps://t.co/MClSjpqpSa Mease and colleagues have catalogued the current practices assessed in the CORRONA registry, noting that increased DMARD switching and decreased time on a given therapy by US physicians. https://t.co/cIWZw6KsuI A retrospective study of systemic sclerosis patients shows that acute hospitalization and mortality were not uncommon and were often linked to SSc-related lung disease. #RheumNow https://t.co/s5wSlndTrt Cases and Questions (AKA Back Talk) “What treatment do you use after 2 years of teraparitide in a woman with a hx of OP, spiral fracture while on a bisphosphonate”? Forteo PI. “Do you have any inside info on the vaccines for COVID-19 during pregnancy?” OCOG Statement “Status of the Tocilizumab Shortage”? Genentech Statement “How would you treat polyarthritis in a renal transplant patient?” CONNECT WITH RheumNow ✩ Website - https://rheumnow.com/ ✩ Subscribe @ RheumNow: https://rheumnow.com/user/register ✩ LinkedIn - https://www.linkedin.com/in/john-cush... ✩ RheumNow LinkedIn: https://www.linkedin.com/company/rheu... ✩ Twitter - https://twitter.com/RheumNow Listen | PODCAST Apple Podcasts: https://podcasts.apple.com/us/podcast... Spotify: https://open.spotify.com/show/4Mjzj5j... Stitcher: https://www.stitcher.com/show/the-rhe... TuneIn: https://tunein.com/podcasts/Health--W... Podbean: https://rheumnow.podbean.com/ Got a Rheumatology question or case for Dr. Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. BackTalk: https://rheumnow.com/submit-podcast-question-or-comment
We've had Dr. Peat on the podcast before, and it actually ended up being our most downloaded WinAtLife podcast. So, we brought him back again to discuss vitamin D, calcium and mineral metabolism. There's so much good information in this one! Dr. Peat offers up a lot of clarity when it comes to the great vitamin D debate. So, should you supplement vitamin D? Should you not? What else should you know when it comes to vitamin D and your metabolic health? As a reminder Vitamin D has many namesThe three most mentioned in this podcast areCholecalciferol also known as D3 (what is in food or supplements)"Stored D" also know as calcidiol / 25OHD /hydroxycholecalciferol"Active D" also know as calcitriol / 1,25DDr. Peat uses the references of 25OHD /hydroxycholecalciferol (stored) and 1,25D (active)In this episode we talk about...➡️ The purpose of Vitamin D➡️ How is vitamin D metabolised and stored➡️ How much D is too much? ➡️ The difference between Active and Stored Vitamin D➡️ Can "stored D" have active properties?➡️ Is elevated Active D (1,25D) a good thing?➡️ Do Vitamin D supplements suppress the immune system?➡️ The Vitamin D "receptor" theory-is it correct?➡️ Are blood levels of stored D (25OHD) correct?➡️ What are optimal stored Vitamin D levels?➡️ The relationship between D and Ca➡️ Understanding the importance of parathyroid hormone (PTH)➡️ What can affect PTH besides Calcium and Vitamin D➡️ What causes calcified tissue➡️ Understanding the calcium -magnesium connection➡️ What ratios, if any, are optimal for minerals?➡️ Understanding Hair Tissue Mineral Analysis? Are they accurate?Check out the entire podcast episode on Apple Podcasts, Spotify, Google Podcast, Stitcher, and iHeart Radio by searching for The Winatlife Podcast.At the end of the podcast, Ray was asked about a study involving Vitamin D supplements and Bone density.Here is the study and his answer:Effect of High-Dose Vitamin D Supplementation on Volumetric Bone Density and Bone StrengthA Randomized Clinical Trial. https://jamanetwork.com/journals/jama/fullarticle/2748796--i"They didn't control their phosphate intake, so it's possible that the high dose D was now and then increasing the 1,25-dihydroxy D, taking some calcium out of the bone. A problem with judging bone mineral content with x-rays is that, in stress, the fat in bone is reduced, and replaced by water, causing more of the x-rays to be absorbed, making the bone seem denser. High-dose vitamin D without extra calcium supplementation has been associated with increased levels of the active vitamin D metabolite 1, 25(OH)2 vitamin D (calcitriol), and an increase in CTx."Buy Kates book: https://nustrength.myshopify.com/products/how-to-heal-your-metabolism-by-kate-deeringDiscount code: KATE10Follow Kitty on Instagram: @kittyblomfieldFollow Kate on Instagram: @katedeeringfitness
Steven Wright is a health engineer and author. In 2009, he reached a breaking point when IBS took over his life and the doctors didn’t know how to help. Since then, he has transformed his health and started HealthyGut.com to help others naturally heal stomach problems. Are you still having gas, bloating & indigestion on the carnivore diet? This episode is for you! Stay tuned for part 2! Links for products discussed with a discount added in (you must purchase each product separately to receive the discount) http://healthygut.com/CHCL http://healthygut.com/CHolozyme http://healthygut.com/CTX
In today's News: LCMS helps Lutherans in Africa Hand washing has been touted as the best way to prevent the spread of the coronavirus. But for people who don’t have regular access to soap and water in public places, this can be a challenge. In April, the Lutheran Church — Missouri Synod (LCMS) approved a grant of $6,250 to the Christ Evangelical Lutheran Church — Sierra Leone to help combat the transmission of covid-19 by increasing public awareness of the need for safety measures such as hand washing and by providing funds to build 154 hand washing stations, one at each church and school. Part of the grant also was used to print and distribute educational materials on good hygiene amid the pandemic. As part of this educational effort, members of the Sierra Leone church are using the Community Health Evangelism curriculum, which pairs health concepts with the gospel. Concordia Texas offers new online degree programs Concordia University Texas (CTX), Austin, Texas, is responding to the realities of covid-19 with two, new fully online degree programs. The Master of Public Health (MPH) is a competency-based graduate program to help meet the demand for public health knowledge and leadership. The Bachelor of Science in Respiratory Care (BSRC) is a degree advancement program for registered respiratory therapists who already hold an associate degree. CTX new online MPH program provides training in eight core competencies, then encourages students to apply them to their own passions, interests and career paths. The 16-month curriculum imparts leadership-level knowledge and skills to teach students how to become policy makers, advocates and change agents. Students can complete a capstone course to gain real-world, hands-on experience in their own specialization or focus. Many health care workers call respiratory therapists the true “heroes of the frontlines” right now, as they provide ventilator support to a high percentage of covid-19 patients. Respiratory therapists also treat any patient with breathing difficulty, often serving those with asthma, respiratory viruses, chronic lung diseases, and in neonatal and intensive care. Respiratory therapists with a two-year degree can now earn a bachelor's degree entirely online through CTX’s degree advancement program. Upcoming cohorts will begin in October 2020 and January 2021. Christian owned company cancels plans Chick-fil-A confirmed this week that the company has canceled plans to open a restaurant at San Antonio International Airport in Texas. On Monday, a spokesperson for the Christian-owned fast-food chain said the company won’t pursue plans at this time to open a restaurant in the airport after city officials last year blocked its plans do so, prompting complaints from the state’s attorney general, the passing of new state law, and an FAA investigation. In March 2019, the San Antonio City Council voted to remove Chick-fil-A from a concession agreement with San Antonio International Airport amid unproven accusations of “anti-LGBT behavior.”
The Australian share market put the brakes on for the 3rd day, as US equities felt weak at the knees for their 2nd session. This follows oil price's massive decline amid oversupply and crippled demand due to COVID-19 lockdowns.Today, the oil price clawed back overnight and the Aussie share market is up 13% from its March lows meaning we are no longer in a bull market. Companies on the ASX leaderboard: WiseTech (ASX:WTC), Pinnacle Investment Management Group (ASX:PNI) and Spark Infrastructure (ASX:SPK).Stocks seeing the most selling: NRW Holdings (ASX:NWH), oOh!Media (ASX:OML) and Stockland (ASX:SGP).Investors are watching GPT Group (ASX:GPT) and Caltex (ASX:CTX).
The Australian sharemarket is having a choppy start to the week and is tracking 1.4% lower before noon, erasing Friday's 1.3% gain. However, for the month of April, the market is still up 6.4%.In Australia, investors will be watching: the Energy sector, Caltex (ASX:CTX), Fortescue Metals (ASX:FMG) and the Staples sector.Looking at the biggest stock moves: AP Eagers (ASX:APE), Nine Entertainment (ASX:NEC), Domain (ASX:DHG) and Southern Cross Media (ASX:SXL).
In this episode, Ingmar and Kees are at Citrix Summit in Orlando. They've interviewed various guests and asked them about their thoughts and opinions on what was shared at the conference. Together with the guests we've talked about Citrix Workspace and the impact of employee experience (but also the partner landscape), diversity, the Microsoft partnership, cloud native networking and the CVE-2019-19781 vulnerability in Citrix ADC/SD-WAN (final fixes released shortly after recording the podcast - https://bit.ly/CVE201919781). Tune in now to satisfy your appetite for EUC!
This weeks highlights include: NFL and NCAAF scores, MLB awards, and soccer. Topics Include: (25:24) we start with the developing news regarding the Astros and sign stealing. We discuss what has been reported and give our thoughts on how serious this is. (51:35) We move into the Colin Kaepernick workout that the NFL recently granted him. Alex and Kevin break down how it went down and get into a heated argument about both sides stories. (1:13:16) It was fight night in Pittsburgh. We discuss the brawl between the Steelers and Browns and give our thoughts on how severe the suspensions and fines should be. (1:23:10) Lastly we welcome Scott Moore to the show via phone. Scott is a soccer coach who has started a youth soccer club called CTX Flash Soccer. Scott tells us about where his love for soccer came from and how it grew. Where the idea came from to start CTX and what motivated him. How his club differs from others. His message to parents and kids. And where he sees soccer going in the future.
Prof Ego Seeman from The University of Melbourne’s Dept of Medicine and Endocrinology talks to GP and RACGP President Dr Harry Nespolon about some of the most effective tests, medications and supplements for the prevention and management of osteoporosis. Prof Seeman is a vocal advocate for GPs to be more involved in osteoporosis management, including using tests such as CTX.
Original broadcast 7/19/17. Todd is always a pleasure to speak with. Very informative episode for Deus and CTX users.Shooters and Prospectorshttps://www.facebook.com/SWShooterSuppliesAndProspecting/XTREME SCOOPShttps://www.facebook.com/XTREMEScoops/DETECTEEShttps://detectees.onlineweb.shop/Beyond_Sight_and_Sound/p5708246_19397084.aspxXP TEAM USAhttps://www.facebook.com/groups/xpdteamusa/XP hard transport case review XP Team USA blog http://xpdeus-usa.com/xp-hard-transport-case-first-impression-and-review-by-josh-kimmel/?fbclid=IwAR3BeogLD3OSgqSZjLrTyAwSVds9fV5V3jrmIqu1Oj8-_SYKiw7GG1Tl_fAXP Team USA Podcast https://www.spreaker.com/show/xp-team-usa-podcasts-show
Original broadcast 7/19/17. Todd is always a pleasure to speak with. Very informative episode for Deus and CTX users.Shooters and Prospectorshttps://www.facebook.com/SWShooterSuppliesAndProspecting/XTREME SCOOPShttps://www.facebook.com/XTREMEScoops/DETECTEEShttps://detectees.onlineweb.shop/Beyond_Sight_and_Sound/p5708246_19397084.aspxXP TEAM USAhttps://www.facebook.com/groups/xpdteamusa/XP hard transport case review XP Team USA blog http://xpdeus-usa.com/xp-hard-transport-case-first-impression-and-review-by-josh-kimmel/?fbclid=IwAR3BeogLD3OSgqSZjLrTyAwSVds9fV5V3jrmIqu1Oj8-_SYKiw7GG1Tl_fAXP Team USA Podcast https://www.spreaker.com/show/xp-team-usa-podcasts-show
Hvordan kan du kontrollere effekten av behandlingen du gir til din osteoporotiske pasient? Hørt om CTX-1 og P1MP? Podcastene er ingen lærebok og kan inneholde feil, generaliseringer og unøyaktigheter som følge av en muntlig overlevering. For nøyaktige anbefalinger må man derfor oppsøke publiserte nasjonale retningslinjer og andre skriftlige kilder i tillegg.
Griekse supporters hebben gisteren vlak voor het duel van Ajax in de Champions League met AEK Athene vuurwerk en projectielen in het vak van de meegereisde Ajax-supporters gegooid. Ook tijdens de wedstrijd zelf ging het er heftig aan toe. "Een deel van het stadion leek wel een oorlogsgebied", zegt NOS-commentator Frank Wielaard. Hij kijkt in De Dag terug op de wedstrijd. "Een Champions League-duel hoort een feestje te zijn. Dat was dit niet." En een eigen medicijn maken tegen de zeldzame stofwisselingsziekte CTX als antwoord op fikse prijsstijgingen. Het plan van het AMC was in april dit jaar een wereldprimeur. Vandaag kreeg het ziekenhuis te horen dat het de productie van het medicijn mag voorzetten, maar wel het productieproces moet aanpassen. "Als het ze lukt het medicijn alsnog te maken, gaan waarschijnlijk meer dure medicijnen nagemaakt worden", zegt redacteur gezondheidszorg Rinke van den Brink in De Dag.
This week, Kyle has us go from football to tricycle! Tim visits the circus while Sky looks at a bunch of unpleasant stress injuries. Yep. Subscribe in iTunesListen on Stitcher Radio
Episode 14 of the Sheffield Digital Podcast is ready for you. It’s a good one, as we interviewed two of the candidates in the upcoming Sheffield City Region mayoral election: Hannah Kitching of the Liberal Democrats and Rob Murphy from The Green Party. We asked them about their plans for the region and, in particular, what they saw for the digital sector in the future. I think you’ll find it an interesting listen and thank you to those of you who sent us questions beforehand. I hope we covered most of your suggestions. It’s worth mentioning that we did ask all four candidates from the major parties. Conservative, Ian Walker, couldn’t make the show, but did record a short response to one of our key questions separately. That follows the conversation with Hannah and Rob. And Labour’s Dan Jarvis declines to come on the podcast, but did take part in a roundtable earlier in the week. Both Chris and Mel were at that meeting and offer their thoughts on what he said in this episode too. After all that, we go through the usual new and events from around Sheffield’s digital community. In particular, Chris offers more detail on the Urban Connected Communities 5G bid following the interview I did with Mark Gannon. I hope you enjoy this rather unique episode and, as always, do get in touch to let us know what you think. Now with chapters! Our episodes are typically split into at least two sections, which include an interview and then the latest news updates. You can now easily skip between these sections if you use an app that supports chapters! Notes and links Every episode comes with a list of links to all of the various people, companies and topics that we reference. Here is that list for episode 13. Hannah Kitching (@HannahK_LD) on Twitter (https://twitter.com/hannahk_ld?lang=en-gb) Councillor Rob Murphy | Sheffield Green Party (https://sheffieldgreenparty.org.uk/about-us/councillors/rob-murphy/) Ian Walker | for Sheffield Hallam (https://www.iangwalker.co.uk/) Dan Jarvis MP (https://www.danjarvis.org/dan_jarvis_for_mayor?splash=1) Coadec | The Policy Voice of Startups (http://www.coadec.com/?COLLCC=990311107) Episode 13: Mark Gannon on dotSHF progress and Sheffield’s Urban 5G Test Bed bid – Sheffield Digital (https://sheffield.digital/posts/mark-gannon-dotshf-5g/) Building a Digital Coalition for Sheffield – Mark Gannon – Medium (https://medium.com/@markgannon/building-a-digital-coalition-for-sheffield-65997ed2a3e7) dotSHF - Sheffield's Digital Coalition - DL100 (https://www.digileaders100.com/nominee/dotshf-sheffields-digital-coalition/) Government seeks major city to lead large-scale urban 5G test project | PublicTechnology.net (https://www.publictechnology.net/articles/news/government-seeks-major-city-lead-large-scale-urban-5g-test-project) CTX is a Sheffield startup with a tool for searching multiple services – Sheffield Digital (https://sheffield.digital/posts/ctx-sheffield-startup-search/) BusinessCloud homepage (http://www.businesscloud.co.uk/) Digital Business Drop-in event in Sheffield on 10th May – Sheffield Digital (https://sheffield.digital/posts/digital-business-drop-in-event-sheffield/) Home - UTC Sheffield (http://www.utcsheffield.org.uk/) Chris Dymond on Twitter: "How many secondary schools have a fully specced Cybersecurity Operations Centre?!” (https://twitter.com/chrisdymond/status/989178443647672325) Meet our members | Sheffield Digital (https://sheffield.digital/membership/meet-our-members/) Become a member of Sheffield Digital (http://sheffield.digital/membership) Did I miss something you’re looking for? Just get in touch and let me know (http://sheffield.digital/contact) . Join the conversation We’re really keen to get your feedback on the podcast. You can Sheffield Digital Slack community (https://sheffield.digital/slack) . Thank you for the music Thanks again to Alex
De kosten van medicijnen rijzen de pan uit. Vooral voor medicijnen tegen zeldzame ziekten. De farmaceutische industrie ligt steeds meer onder vuur, omdat ze de prijzen voor nieuwe geneesmiddelen kunstmatig op zouden drijven, soms tot absurde hoogten. Deze week maakte het AMC bekend dat het ziekenhuis in samenwerking met stichting Pharmagister er in geslaagd is om zelf het geneesmiddel te maken tegen de zeldzame stofwisselingsziekte CTX. Het middel CDCA, dat door farmafabrikant Leadiant wordt aangeboden, kost 160.000 tot 220.000 Euro per patiënt per jaar. Als de apotheek van het AMC het middel maakt kost het ongeveer 25.000 Euro. Is wat het AMC doet niet in strijd met de regels die gelden voor de toelating van geneesmiddelen? Waarom zijn geneesmiddelen zo duur? Ligt dit uitsluitend aan de winsthonger van de farmaceutische industrie? Kunnen ook andere dure geneesmiddelen worden nagemaakt door ziekenhuizen of apothekers? Wat zijn de drempels?
De kosten van medicijnen rijzen de pan uit. Vooral voor medicijnen tegen zeldzame ziekten. De farmaceutische industrie ligt steeds meer onder vuur, omdat ze de prijzen voor nieuwe geneesmiddelen kunstmatig op zouden drijven, soms tot absurde hoogten. Deze week maakte het AMC bekend dat het ziekenhuis in samenwerking met stichting Pharmagister er in geslaagd is om zelf het geneesmiddel te maken tegen de zeldzame stofwisselingsziekte CTX. Het middel CDCA, dat door farmafabrikant Leadiant wordt aangeboden, kost 160.000 tot 220.000 Euro per patiënt per jaar. Als de apotheek van het AMC het middel maakt kost het ongeveer 25.000 Euro. Is wat het AMC doet niet in strijd met de regels die gelden voor de toelating van geneesmiddelen? Waarom zijn geneesmiddelen zo duur? Ligt dit uitsluitend aan de winsthonger van de farmaceutische industrie? Kunnen ook andere dure geneesmiddelen worden nagemaakt door ziekenhuizen of apothekers? Wat zijn de drempels?
We've been busy giving away tickets to see R.L. Griffin this weekend at the Harker Heights Event Center for all the Southern Soul and Blues fans in the CTX!
PETE ANDERSON OF ANDERSON SHAFTS We are excited and looking forward to speaking with Mr. Pete Anderson of Anderson shafts! As you know, Anderson shafts have been around for awhile now and making some great after market accessories such as dive shafts, lower shafts, scoop handles and more! Check out their website at: http://andersondetectorshafts.com/ Recently Anderson shafts has even released a lower shaft for the Minelab CTX 3030 and I'm sure we will be speaking some about it as well as their lower for the AT PRO and more. I myself have been very interested in the new lower CTX 3030 shaft and wil be interested in hearing what Pete has to share with us about it and the rest of the Anderson shafts lineup! Join us! Tune in...we want to hear from you!Call in number is 1-419-549-5744
Wed, March 2nd, 2016...8:00 PM Eastern Time... BEYOND SIGHT AND SOUND....with Josh Kimmel and Leighton HarringtonTREVOR FERRARESSO OF COILTEK COILSI'm sure you've heard of COILTEK coils and have even heard them mentioned during the show many times as both Leighton and myself really like that 10x5 Coiltek for the CTX. If you have had the chance to catch Trevor on BEYOND SIGHT AND SOUND or even any of the other shows he's dropped by then you know that not only is he very energetic about the hobby of metal detecting,...he's also serious about COILTEK coils. Coiltek has been manufacturing high performance aftermarket coils and accessories for some time now and continue to optimize discovery with their intense research and development of these great products that continue to produce many nice finds for those of us who continue to use their products in the field where it counts! The last time Trevor was on the show we had a great time speaking with him and even a few laughs with the future / past understanding of time zone difference. Trevor had mentioned that there were some things that Coiltek had been working on the last time he was on the show so maybe we will get to hear more about these things or even some of what's on the horizon for Coiltek. One things is for sure...it will be great to speak with Trevor again and we are looking forward to speaking with him. Join us as BEYOND SIGHT AND SOUND heads across the pond for another fun and informative show about COILTEK! Tune in...we want to hear from you!Join us live...Wed, March 2nd, 8 PM EasternCall in number is 1-419-549-5744I hope to see you there...call in, interact, or just sit back and listen!Click the link below to listen to the show, live through the player... Coiltek 10x5 coil promohttps://www.youtube.com/watch?v=RgBxh8imsrc
© 2020-2025 Ivy Podcast Discovery LLC
